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Standard for Evaluating Patent
Litigants' Access to the Declaratory
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By LISA A. DoIAK*
IN LIMITING PATENT LITIGANTS' ACCESS to the declaratory
judgment remedy, the United States Court of Appeals for the Federal
Circuit has primarily invoked the "actual controversy" requirement
imposed by the United States Constitution and the Federal Declara-
tory Judgment Act (the "Act").' However, an examination of Federal
Circuit decisions and those of the district courts reveals that they have
often confused, or blurred the distinction between, constitutional re-
quirements and the discretion the Act affords the federal courts to
decline to exercise jurisdiction. Specifically, the courts have often at-
tributed constitutional significance to factors that instead bear on pol-
icy, conflating issues of power with those of prudence.
The role that policy plays in patent declaratory justiciability deter-
minations was at issue in two cases that were recently pending before
the United States Supreme Court. For example, in MedImmune, Inc. v.
Genentech, Inc.,2 the Solicitor General criticized the Federal Circuit for
its reliance on patent policy in deciding justiciability. 3 And the peti-
tioner in Apotex, Inc. v. Pfizer Inc.4 accused the court of "elevat[ing]
that court's prudential jurisdictional doctrine (the 'reasonable appre-
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1. The Declaratory Judgment Act is codified at 28 U.S.C. § 2201 (2000).
2. 427 F.3d 958 (Fed. Cir. 2005), cert. granted, No. 05-608, 126 S. Ct. 1329 (2006),
rev'd and remanded, 2007 IWL 43797, No. 05-608 (U.S. Jan. 9, 2007).
3. Brief for the United States as Amicus Curiae Supporting Petitioner at 23, MedIm-
mune, Inc. v. Genentech, Inc., 2006 WL 1327303 (U.S. May 15, 2006) (No. 05-608) ("Con-
siderations of patent policy . . .could not justify creation of a patent-specific test that is
more rigorous than the constitutional and statutory standards that determine the existence
of ajusticiable case or controversy in all other contexts.").
4. 159 F. App'x 1013 (Fed. Cir. 2005), cert. denied, 127 S. Ct. 379 (2006).
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hension' requirement) to a 'constitutional requirement.' 5 But, as dis-
cussed herein, the Federal Circuit's intermingling of jurisdiction and
policy is not confined to these two cases.
The courts should distinguish between jurisdictional limits and
policy considerations when they decide justiciability issues in patent
cases. Misapplication of the law, or even mere imprecision in the allo-
cation of jurisdictional and prudential considerations, engenders con-
fusion among the affected parties-litigants and potential litigants-
who then bear the costs of this confusion in the form of uncertainty,
higher litigation expenses, and forgone opportunities. If the courts
attend to the distinction between the jurisdictional and prudential ba-
ses for justiciability decisions, the likely results include the develop-
ment of better policy and improved judicial decision-making.
This Article discusses the Federal Circuit's treatment of the jus-
ticiability of declaratory judgment claims in patent cases. Part I ex-
plains the jurisdictional and discretionary standards the courts have
applied in determining whether to adjudicate declaratory judgment
claims. It further describes how the Federal Circuit has generally ap-
plied the jurisdictional standards restrictively. Part II illustrates that
the courts have often decided cases on jurisdictional grounds when
the underlying facts have principally or exclusively prudential signifi-
cance. Part III posits that negative jurisprudential and practical conse-
quences flow from this tendency. Part III then seeks to explain how
these consequences result in detrimental effects on the vitality of the
United States patent system. Part III further contends that by separat-
ing their analyses of jurisdictional and prudential considerations,
courts can arrive at better decisions concerning the justiciability of
declaratory judgment claims in patent infringement disputes.
I. The Challenge for the Patent Challenger
A. The Declaratory Judgment Act
In the years leading up to 1934, Congress expressed its desire to
alleviate the uncertainty faced by parties, such as alleged patent in-
fringers, who previously lacked a cause of action, and were, therefore,
unable to secure judicial determination of their rights.6 That desire
5. Petition for a Writ of Certiorari at 8-9, Apotex, Inc. v. Pfizer Inc., 127 S. Ct. 379
(2006) (No. 05-1006), available at 2006 WL 304672.
6. Act of June 14, 1934, ch. 512, 48 Stat. 955 (current version at 28 U.S.C. § 2201
(2000)). The legislative history from the 1934 Congressional session is very limited because
there were no debates in either the House or the Senate on the bill that year. See 78 CONG.
Rac. 10,564-65, 10,919 (1934) (Senate consideration); 78 CONG. Rrc. 8224 (1934) (House
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became a primary motivating force behind the federal Declaratory
Judgment Act.7
The Act's sole requisite for jurisdiction is the presence of an ac-
tual controversy.8 In other words, to qualify for adjudication pursuant
to the Act, a dispute must satisfy the constitutional "case or contro-
versy" requirement.9 However, while the existence of declaratoryjudg-
consideration). However, a bill proposing a federal declaratory judgment remedy had
been introduced in every Congressional session from 1919 to 1932, and the corresponding
hearings demonstrate that the primary purpose of the statute was to eliminate uncertainty.
See, e.g., 1928 Hearings on H.R. 5623 Before a Subcomm. of the Senate Comm. on the Judiciary,
70th Cong. 34-35 (1928) [hereinafter 1928 Senate Hearings] (testimony of Professor Edson
R. Sunderland, whose 1917 law review article, Edson R. Sunderland, A Modern Evolution in
Remedial Rights-The Declaratory Judgment, 16 MICH. L. REv. 69 (1917), was instrumental in
instituting the effort to pass a federal declaratory judgment statute in the United States)
(contending that, without the declaratory judgment remedy, parties must undergo great
risks without knowledge of the respective entitlements and concluding that the declaratory
judgment "removes all that peril"); 1928 Senate Hearings, supra, at 16 (referencing a letter
from Judge Cardozo, then Chief Judge of the New York State Court of Appeals, that de-
scribed the remedy as "a useful expedient to litigants who would otherwise have acted at
their peril, or at best would have been exposed to harrowing delay"); Hearing on H.R.
10143 Before the House Comm. on the Judiciary, 67th Cong. 16 (1922) [hereinafter 1922 House
Hearings] (statement of Rep. Sumners) (noting that the purpose of the declaratory judg-
ment statute is "[t]o remove uncertainty" and that "the individual citizen has as much right
to be reasonably certain as to what the courts would determine his rights to be as he has to
be reasonably certain what the legislature has determined his rights to be"). In his Senate
testimony, Professor Sunderland described the plight of the alleged patent infringer, as
follows:
I assert that I have a right to use a certain patent. You claim that you have a
patent. What am I going to do about it? There is no way I can litigate my right,
which I claim, to use that device, except by going ahead and using it, and you [the
patent holder] can sit back as long as you please and let me run up just as high a
bill of damages as you wish to have me run up, and then you may sue me for the
damages, and I am ruined, having acted all the time in good faith and on my best
judgment, but having no way in the world to find out whether I had a right to use
that device or not.
1928 Senate Hearings, supra, at 35.
7. The Act provides, in relevant part:
Creation of remedy
(a) In a case of actual controversy within its jurisdiction, . . .any court of the
United States, upon the filing of an appropriate pleading, may declare the rights
and other legal relations of any interested party seeking such declaration,
whether or not further relief is or could be sought. Any such declaration shall
have the force and effect of a final judgment or decree and shall be reviewable as
such.
28 U.S.C. § 2201 (2000).
8. Id.
9. SeeAetna Life Ins. Co. v. Haworth, 300 U.S. 227, 239-40 (1937) (interpreting the
Act's application in an action brought by an insurance company against its insured and his
beneficiary); see also Societe de Conditionnement en Aluminium v. Hunter Eng'g Co., 655
F.2d 938, 942 (9th Cir. 1981) (noting that the Act's actual controversy requirement "is the
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ment jurisdiction is an either/or proposition, many cases do not
definitively fit into one category or the other'10 Hence, to assist their
justiciability evaluations, the courts have developed more particular-
ized standards for determining whether an actual controversy sup-
ports a declaratory judgment claim.
A patent infringement defendant typically asserts one or more
declaratory judgment counterclaims in response to the patentee's
claim(s) for patent infringement. Most commonly, infringement de-
fendants request judgment on the ground that the patent at issue is
invalid,11 unenforceable, 12 and/or not infringed.13 Alternatively, a
patent challenger may, in appropriate circumstances,1 4 institute pat-
same as the 'case or controversy' requirement of Article III of the United States Constitu-
tion"); Precision Shooting Equip. Co. v. Allen, 646 F.2d 313, 314 n.4 (7th Cir. 1981) (ob-
serving that "[t]he Declaratory Judgment Act . . . limits declaratory judgments to actual
controversies in conformity with Article III, Section 2 of the Constitution").
10. See BP Chem. Ltd. v. Union Carbide Corp., 4 F.3d 975, 978 (Fed. Cir. 1993) (not-
ing that the difference between an actual controversy and a situation not ripe for adjudica-
tion "'is necessarily one of degree' . . . and is determined on the totality of the
circumstances") (quoting Md. Cas. Co. v. Pac. Coal & Oil Co., 312 U.S. 270, 273 (1941));
see also Precision Shooting, 646 F.2d at 316 (stating that "the application of the general 'con-
troversy' rule to a particular patent matter is not easy and may involve a determination of
whether in a gray area the gray is dark enough").
11. See, e.g., Biocore, AB v. Thermo Bioanalysis Corp., 79 F. Supp. 2d 422, 426 (D. Del.
1999) (noting that the infringement defendant pled invalidity and noninfringement coun-
terclaims). Invalidity results from the failure of the patent to meet one or more statutory
requirements, including, for example, the requirements that: (1) the claims recite novel
and nonobvious subject matter; (2) the specification enable, provide a written description
for, and disclose the best mode (if there is one) of practicing the claimed invention; and
(3) the claims "particularly [point] out and distinctly [claim]" the subject invention. 35
U.S.C. §§ 102-03, 112 (2000).
12. See, e.g., Glaxo Wellcome, Inc. v. Pharmadyne Corp., 32 F. Supp. 2d 265, 268-71
(D. Md. 1998) (introducing findings of fact and conclusions of law in a patent infringe-
ment case in which the infringement defendants sought a declaratory judgment that the
plaintiff's patents were invalid, unenforceable, or not infringed). A patent may be declared
unenforceable based, for example, on the applicant's inequitable conduct during procure-
ment. See, e.g., Elk Corp. v. GAF Bldg. Materials Corp., 168 F.3d 28, 32 (Fed. Cir. 1999)
(affirming determination of inequitable conduct based on applicant's failure to disclose its
own prior art patent and reference located in patentability search).
13. See, e.g., Evans Med. Ltd. v. Am. Cyanamid Co., 980 F. Supp. 132, 138 (S.D.N.Y.
1997) (dismissing defendants's declaratory judgment counterclaims based on allegations
that the asserted patents were invalid, unenforceable, and not infringed); see 35 U.S.C.
§ 271 (a) (2000) (" [W] hoever without authority makes, uses, offers to sell, or sells any pat-
ented invention, within the United States or imports into the United States any patented
invention during the term of the patent therefor [sic], infringes the patent.").
14. See infta notes 17-34 and accompanying text.
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ent litigation in federal court 15 by filing a complaint requesting a dec-
laration of patent invalidity, unenforceability, or noninfringement.16
B. Invoking the Patent Declaratory Judgment Jurisdiction of the
District Courts
When a party seeks to challenge a patent by way of a declaratory
judgment claim, it must convince a district court that the situation
meets the Federal Circuit's two-part jurisdictional test. The Federal
Circuit has described the task as follows: "First, the [patentee's] con-
duct must have created on the part of [the] plaintiff a reasonable ap-
prehension that the [patentee] will initiate suit if the plaintiff
continues the allegedly infringing activity. Second, the plaintiff must
have actually ... either produced the device or have prepared to pro-
duce the device." 17
Thus, the first prong, the "reasonable apprehension" prong of
the test, has focused on the patentee's conduct, 18 while the second
prong, the "infringer activity" prong, has looked to the conduct of the
challenger. 19
15. The federal courts have exclusive jurisdiction over cases arising under the patent
laws. See 28 U.S.C. § 1338 (a) (2000). According to the Federal Circuit, "[a] n action seeking
declaration of patent invalidity arises under the patent law,.., as do actions seeking decla-
ration of infringement, ... and declaration of noninfringement." Genentech, Inc. v. Eli
Lilly & Co., 998 F.2d 931, 943 (Fed. Cir. 1993) (citing EDWIN BORCHARD, DECLARATORY
JUDGMENTS 808 (2d ed. 1941)).
16. "Easily the most common kind of [declaratory judgment] action .... is a suit by
one thought to be an infringer for a declaration that he is not infringing the patent or that
the patent is invalid." 1OB CHARLES A. WRIGHT ET AL., FEDERAL PRACTICE AND PROCEDURE
§ 2761, at 573 (3d ed. 1998). See, e.g., Minds-Eye-View, Inc. v. Interactive Pictures Corp., 58
F. Supp. 2d 5, 10 (N.D.N.Y. 1999) (granting defendant-patentee's motion to dismiss al-
leged infringers's declaratory judgment invalidity claim); Epling v. Golden Eagle/Satellite
Archery, Inc., 17 F. Supp. 2d 207, 211 (W.D.N.Y. 1998) (denying defendant-patentee's mo-
tion to dismiss or stay competitor's action seeking a declaratory judgment of noninfringe-
ment); CAE Screenplates, Inc. v. Beloit Corp., 957 F. Supp. 784, 790 (E.D. Va. 1997)
(denying plaintiff-putative infringer's motion to compel discovery from defendant-paten-
tee in order to establish subject matter jurisdiction over the plaintiffs claim for a declara-
tion that the patent was invalid, unenforceable, and not infringed).
17. Arrowhead Indus. Water, Inc. v. Ecolochem, Inc., 846 F.2d 731, 736 (Fed. Cir.
1988).
18. Id. It is important to recognize that an individual patent challenger's subjective
apprehension has not been relevant to the actual controversy inquiry. See Phillips Plastics
Corp. v. Kato Hatsujou Kabushiki Kaisha, 57 F.3d 1051, 1053-54 (Fed. Cir. 1995) ("The
,reasonable apprehension of suit' test requires more than the nervous state of mind of a
possible infringer; it requires that the objective circumstances support such an
apprehension.").
19. Reflecting the difficulties associated with articulating a workable and universally
applicable standard for evaluating the "infringer activity" prong of the actual controversy
test, the Federal Circuit has described this requirement variously as whether the declara-
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Even if a court determines that an actual controversy exists, the
Act does not require the court to decide the merits of the request for
declaratory relief.20 Whether to exercise jurisdiction lies in the court's
discretion. At the same time, however, the Federal Circuit has ac-
knowledged that the discretion afforded by the Act is not unfet-
tered. 21 In the words of the court, "The exercise of discretion in a
declaratory judgment must have a basis in sound reason." 22
tory plaintiff has engaged in "present activity which could constitute infringement or con-
crete steps taken with the intent to conduct such activity." BP Chem. Ltd. v. Union Carbide
Corp., 4 F.3d 975, 978 (Fed. Cir. 1993) (citingJervis B. Webb Co. v. Southern Sys., Inc., 742
F.2d 1388, 1398-99 (Fed. Cir. 1984)); seeGenentech, Inc. v. Eli Lilly and Co., 998 F.2d 931,
936 (Fed. Cir. 1993) (describing the requirement as "whether the declaratory plaintiff has
acted in a way that the patentee asserts infringes the patent, or is preparing to act in such a
way" (citing Arrowhead, 846 F.2d at 735-36)); Arrowhead, 846 F.2d at 736 (describing the
requirement as whether the "[p]laintiff [has] engaged in an actual making, selling, or
using activity subject to an infringement charge or [has] made meaningful preparation for
such activity" (citing Indium Corp. v. Semi-Alloys, Inc., 781 F.2d 879, 883 (Fed. Cir. 1985));
Arrowhead, 846 F.2d at 738 n.10 (describing the requirement as whether the "plaintiffs
conduct evidences a real interest in an activity that may, potentially, be enjoined"); Jervis B.
Webb, 742 F.2d at 1399 (describing the requirement as whether the "plaintiff ... actually
produced the accused device or . . .actually prepared to produce such a device" (citing
Sweetheart Plastics, Inc. v. Illinois Tool Works, Inc., 439 F.2d 871, 875 (1st Cir. 1971)); see
also Int'l Harvester Co. v. Deere & Co., 623 F.2d 1207, 1210 (7th Cir. 1980) (describing the
requirement as whether the declaratory plaintiff "actually produced the accused article
or... engaged in preparations for production such that 'but for a finding that the product
infringes or for extraordinary and unforeseen contingencies, the plaintiff would and could
begin production immediately"' (citing Sweetheart Plastics, 439 F.2d at 875)); Wembley, Inc.
v. Superba Cravats, Inc., 315 F.2d 87, 89 (2d Cir. 1963) (citations omitted) (describing the
requirement as whether the plaintiff is "engaged in manufacturing, using or selling the
invention, or... has the immediate intention and ability to do so" and noting that "early
cases required that plaintiff actually be engaged in infringing conduct, [but] this is no
longer the law").
20. See MedImmune, Inc. v. Genentech, Inc., No. 05-608, slip op. at 17 (U.S. Jan. 9,
2007), available at 2007 WL 43797; Public Serv. Comm'n v. Wycoff Co., 344 U.S. 237, 241
(1952).
21. See Genentech, 998 F.2d at 936 (noting that "the court cannot refuse to entertain a
declaratory judgment action on a whim" (quoting 10A WRIGHT ET AL., supra note 16,
§ 2759, at 655-56 (2d. ed 1983)) and that "[t]he determination of the trial court may,
therefore, be reversed where, though not arbitrary or capricious, it was nevertheless erro-
neous" (citing 6AJAMES W. MOORE ET AL., MooPE's FEDERAL PRACTICE 57.08[2], at 57-36
(2d ed. 1993))).
22. Genentech, 998 F.2d at 936 (citing Samuel Goldwyn, Inc. v. United Artists Corp.,
113 F.2d 703, 709 (3d Cir. 1940)). Although the Supreme Court held that district courts
enjoy a "unique breadth" of discretion to decline jurisdiction under the Declaratory Judg-
ment Act, the Court expressly declined to "delineate the outer boundaries of that discre-
tion in other cases, for example, cases raising issues of federal law or cases in which there
are no parallel state proceedings." Wilton v. Seven Falls Co., 515 U.S. 277, 290 (1995). This
comment is instructive with respect to declaratory judgment claims in patent cases. Most
such claims are based on federal law, and coincident parallel state court proceedings will
be relatively rare, given the federal courts's exclusive jurisdiction in patent cases. See 28
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C. The Federal Circuit's "Reasonable Apprehension" Test
When an alleged patent infringer presents its request for declara-
tory relief as a counterclaim to a claim for patent infringement, the
courts, for obvious reasons, usually have not found it necessary to elab-
orate on whether the defendant had a reasonable apprehension of
suit. However, when the patent challenger initiates the litigation, the
jurisdictional inquiry has most often turned on whether the plaintiff
alleged, 23 and in fact had, 24 the requisite reasonable concern.
The requisites for satisfying this prong of the actual controversy
test in patent cases have evolved.2 5 Prior to the creation of the Federal
Circuit, the courts generally found an actual controversy to exist
whenever the patentee had accused the declaratory judgment plaintiff
of infringement.2 6 Yet, sometimes courts found jurisdiction to lie in
the absence of such a charge, and, in some cases, the patentee did not
even know of the plaintiffs activities relevant to the patent.2 7
In contrast, the Federal Circuit has held that a notice letter stat-
ing a party's products "may infringe" certain patents does not create
an actual controversy. 28 In the court's view, even unequivocal asser-
tions that products "fall within," that "operations [are] under," or that
products are "covered by" specified patents have been insufficient to
U.S.C. § 1338(a) (2000). Thus, it is not clear that the Supreme Court would uphold a
broad exercise of discretion to decline to hear an accused infringer's action for a declara-
tion of patent invalidity or non-infringement where a patentee has asserted infringement
and the accused infringer has access to no other forum.
23. The party invoking the jurisdiction of the district court must plead the "grounds
upon which the court's jurisdiction depends." See FED. R. Civ. P. 8.
24. The challenger-plaintiff is put to its proof if the patentee-defendant challenges
the existence of an actual controversy. SeeJervis B. Webb Co. v. Southern Sys., Inc., 742
F.2d 1388, 1399 (Fed. Cir. 1984) (stating that "where... the declaratory defendant (paten-
tee) has denied the factual allegations that allegedly support the existence of case or con-
troversy, the declaratory plaintiff must prove the existence of facts underlying such
allegations"); see also K-Lath v. Davis Wire Corp., 15 F. Supp. 2d 952, 958 (C.D. Cal. 1998)
(noting that "[w]hen considering a Rule 12(b) (1) motion challenging the substance of
jurisdictional allegations, the Court is not restricted to the face of the pleadings, but may
review any evidence, such as declarations and testimony, to resolve any factual disputes
concerning the existence ofjurisdiction" (citing McCarthy v. United States, 850 F.2d 558,
560 (9th Cir. 1988))).
25. See Lisa A. Dolak, Declaratory Judgment Jurisdiction in Patent Cases: Restoring the Bal-
ance Between the Patentee and the Accused Infringer, 38 B.C. L. REv. 903, 917-932 (1997).
26. See id. at 917-22.
27. See id.
28. See, e.g., SRI Int'l, Inc. v. Advanced Tech. Lab., Inc., 127 F.3d 1462, 1469-70 (Fed.
Cir. 1997) (finding that a letter offering a nonexclusive license and requesting "some in-
sight into [the letter recipient's] reasons" in support of any view that no license is needed
did not constitute an actual controversy).
Winter 2007] POWER OR PRUDENCE
UNIVERSITY OF SAN FRANCISCO LAW REVIEW
create jurisdiction-at least if they are made during negotiations be-
tween the parties. 29
The Federal Circuit's articulated standard has transparently re-
flected this evolution. Before and since the creation of the Federal
Circuit, the circuit courts of appeal generally looked for a "reasonable
apprehension of liability" on the part of the declaratory judgment
plaintiff.30 This differs from the Federal Circuit's standard, which has
called for the plaintiff to demonstrate a "reasonable apprehension
that it will face an infringement Suit.'' 31 Thus, the Federal Circuit has fo-
cused on the plaintiffs reasonable fear of litigation, rather than a fear
29. See, e.g., Phillips Plastics Corp. v. Kato Hatsujou Kabushiki Kaisha, 57 F.3d 1051,
1053-54 (Fed. Cir. 1995) (quoting Shell Oil Co. v. Amoco Corp., 970 F.2d 885, 888-89
(Fed. Cir. 1992)).
30. See, e.g., Societe de Conditionnement en Aluminium v. Hunter Eng'g Co., 655
F.2d 938, 944 (9th Cir. 1981) (emphasis added) ("An action for a declaratory judgment
that a patent is invalid, or that the plaintiff is not infringing, is a case or controversy if the
plaintiff has a real and reasonable apprehension that he will be subject to liability if he
continues to manufacture his product."); TRW, Inc. v. Ellipse Corp., 495 F.2d 314, 320 (7th
Cir. 1974) (noting that "a reasonable apprehension of liability" is "the 'touchstone' for
determining jurisdiction under the Declaratory Judgment Act"); Diamond Shamrock
Corp. v. Lumbermens Mut. Cas. Co., 416 F.2d 707, 709 (7th Cir. 1969) (stating "the test for
availability of declaratory judgment [is] whether there is 'reasonable apprehension of lia-
bility'"). But see Grafon Corp. v. Hausermann, 602 F.2d 781, 784-85 (7th Cir. 1979) (recit-
ing a "reasonable ... fear [of] an infringement suit or the threat of one" and holding that
the district court had jurisdiction where the patentees had contacted the plaintiffs custom-
ers and potential customers and "notif[ied] them that [the plaintiff] no longer had any
rights under the... patents" or that the patentees "were seeking an injunction to prohibit
[the plaintiff] from producing [the machines at issue]"). For a more recent application of
the "reasonable apprehension of liability" standard outside the Federal Circuit, see Starter
Corp. v. Converse, Inc., 84 F.3d 592, 595 (2d Cir. 1996) ("In a declaratory judgment action
involving trademarks, the test for an 'actual case or controversy' has two prongs, both of
which must be satisfied in order to establish declaratory judgment jurisdiction: (1) has the
defendant's conduct created a real and reasonable apprehension of liability on the part of
the plaintiff, and (2) has the plaintiff engaged in a course of conduct which has brought it
into adversarial conflict with the defendant.").
31. Indium Corp. v. Semi-Alloys, Inc., 781 F.2d 879, 883 (Fed. Cir. 1985) (emphasis
added) (quotingJervis B. Webb Co. v. Southern Sys., Inc., 742 F.2d 1388, 1398-99 (Fed.
Cir. 1984)); see also Cygnus Therapeutic Sys. v. Alza Corp., 92 F.3d 1153, 1159 (Fed. Cir.
1996) ("[A]n actual controversy exists if there is . . . an explicit threat or other action by
the patentee, which creates a reasonable apprehension on the part of the declaratory
plaintiff that it will face an infringement suit. .. ."). As the Solicitor General observed in
his recent amicus brief supporting the petitioner in MedImmune, Inc. v. Genentech, Inc., the
Federal Circuit in one recent case raised the articulated jurisdictional bar even further.
Brief for the United States as Amicus Curiae Supporting Petitioner, supra note 3, at 15 n.8
(citing Teva Pharm. USA, Inc. v. Pfizer Inc., 395 F.3d 1324, 1333-34 (Fed. Cir. 2004) ("In
order for this case to be one fit for judicial review, [the putative infringer] must be able to
demonstrate that it has a reasonable apprehension of imminent suit.")).
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of ultimate liability.32 Moreover, in recent cases, the court has made
the plaintiff prove that the patentee's "explicit threat" of litigation cre-
ated its reasonable apprehension, as contrasted with showing an "ex-
press charge" of infringement-the standard previously applied by the
court.33 The departure from earlier holdings is more significant when
one considers that pre-Federal Circuit cases merely required proof of
a "charge of infringement," or even less. 34
Thus, the Federal Circuit's ruling in MedImmune, Inc. v. Genentech,
Inc.35 came as no surprise. In 1997, MedImmune and Genentech
agreed that MedImmune would license several patents from
Genentech, including the "Cabilly I" patent.36 The license agreement
also included several pending Genentech patent applications, the
claims of which were not yet finalized. 37 After one of those patent ap-
plications matured into the "Cabilly II" patent, Genentech notified
MedImmune that the Cabilly II patent covered MedImmune's
Synagis® product and that the license agreement therefore required
MedImmune to pay royalties on that product.38 MedImmune dis-
agreed and-while continuing to pay the license royalties-filed an
action requesting a declaratory judgment that the Cabilly II patent was
invalid or unenforceable. 39
The Federal Circuit affirmed the district court's grant of
Genentech's motion to dismiss for lack of subject matter jurisdiction,
stating, "The district court did not err in holding that MedImmune,
since under no threat or apprehension of suit, did not have standing
to bring a declaratory challenge to the Cabilly II patent. '40 The court
32. The difference is significant because the court's more restrictive interpretation of
the Declaratory Judgment Act is inconsistent with the Act's purposes, and it can leave the
accused patent infringer in the position of accruing liability for damages but without a
forum for airing allegations of invalidity and/or non-infringement. See Dolak, supra note
25, at 932-48. The Federal Circuit has never explained why it believes that a reasonable
apprehension of suit, as opposed to liability, is required by the Act or the Constitution.
33. See Dolak, supra note 25, at 923-32. The Federal Circuit has continued to articu-
late the "express charge" standard, and it has disavowed the notion that it requires that the
"patentee be known to be poised on the courthouse steps." See Dolak, supra note 25, at
928-31. However, its decisions have demonstrated that an express infringement charge
may not be sufficient. See supra notes 28-29 and accompanying text.
34. See supra notes 25-27 and accompanying text.
35. 427 F.3d 958 (Fed. Cir. 2005), rev'd and remanded, No. 05-608, 2007 WL 43797, at
*1 (U.S. Jan. 9, 2007).
36. Petition for a Writ of Certiorari at 4, MedImmune, Inc. v. Genentech, Inc., 126 S.
Ct. 1329 (2006) (No. 05-608), available at 2005 WL 3067195.
37. Id.
38. Medlmmune, 427 F.3d at 962.
39. Id.
40. Id. at 965.
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relied on its prior decisions in Gen-Probe, Inc. v. Vysis, InC.41 and Medlm-
mune, Inc. v. Centocor, Inc. ("Centocor"), 42 each of which involved declar-
atory judgment actions brought by non-breaching licensees.
In Gen-Probe, the Federal Circuit invoked its "reasonable appre-
hension/infringer activity" test and held that "th[e] license, unless
materially breached, obliterated any reasonable apprehension of a
lawsuit. ... -43 Similarly, in Centocor, the court held that "[a] ny contro-
versy that may have existed between MedImmune and Centocor prior
to and during their various negotiations vanished when MedImmune
executed the license agreement, which is a covenant by Centocor not
to sue."
44
Much like its decision in MedImmune, the Federal Circuit's dispo-
sition in another patent declaratory judgment case, Apotex, Inc. v. Pfi-
zer Inc.,45 was also fairly predictable. Apotex involved a generic drug
manufacturer's effort to invalidate an "Orange Book" listed patent.46
41. 359 F.3d 1376 (Fed. Cir. 2004) (holding that a district court lacks jurisdiction to
entertain a declaratory judgment action brought by a licensee in good standing against its
licensor).
42. 409 F.3d 1376 (Fed. Cir. 2005). After accepting a license from Centocor, Medlm-
mune asserted that the licensed product did not infringe the licensed patent and that the
patent was invalid and/or unenforceable, and filed a declaratoryjudgment action (without
ceasing royalty payments) when Centocor held MedImmune to its license obligations. Id.
at 1378.
43. Gen-Probe, 359 F.3d at 1381.
44. Centocor, 409 F.3d at 1379.
45. 159 F. App'x 1013 (Fed. Cir. 2005), cert. denied, 127 S. Ct. 379 (2006).
46. Pursuant to portions of the Drug Price Competition and Patent Term Restoration
Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585 (1984) (codified at 21 U.S.C. §§ 355, 360cc
(2000); 35 U.S.C. §§ 156, 271, 282 (2000)), a brand-name drug manufacturer who has
obtained Food & Drug Administration ("FDA") marketing approval for its drug product
through the FDA "New Drug Application" ("NDA") approval process must notify the FDA
of all patents that "claim [ I the drug for which the [NDA] applicant submitted the applica-
tion .. .and with respect to which a claim of patent infringement could reasonably be
asserted ...." 21 U.S.C. § 355(b) (1), (c) (2). The FDA publication that identifies such
patents is known as the "Orange Book." A generic drug manufacturer who wishes to utilize
the FDA's "Abbreviated New Drug Application" ("ANDA") process (and thereby obtain
marketing approval for the generic drug product by virtue of its bioequivalence with the
NDA-approved drug) must certify
(I) that such [Orange Book] patent information has not been filed, (II) that such
patent has expired, (III) .. .the date on which such patent will expire, or (IV)
that such patent is invalid or will not be infringed by the manufacture, use, or sale
of the new drug for which the application is submitted ....
21 U.S.C. § 355(j) (2) (A) (vii) (I-IV). Under 35 U.S.C. § 271(e) (2) (A), the filing of an
ANDA "for a drug claimed in a patent" constitutes an act of patent infringement if the
ANDA applicant seeks approval to market the generic drug before the expiration of the
patent(s) at issue (i.e., files a "Paragraph IV" certification). If the patent owner does not
file suit against the ANDA applicant within forty-five days after receiving the required no-
tice of the ANDA filing, the FDA is authorized to approve the ANDA. 21 U.S.C.
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Pfizer, the NDA holder, avoided suing Apotex, the ANDA applicant,
even after receiving the Apotex notice of its ANDA filing/Paragraph
IV certification. 47 Instead, Pfizer sued WAX, the first ANDA applicant
for the drug at issue, and settled that lawsuit by agreeing that WAX
would be licensed under the Pfizer patent effective as of the expira-
tion of an earlier Pfizer patent covering the same drug product. 48 The
applicable statutory scheme entitled IVAX, as the first ANDA appli-
cant, to a 180-day period of marketing exclusivity.49 Specifically, in this
circumstance, the statute barred the FDA from approving the Apotex
ANDA until the earlier of either the end of WAX's market exclusivity
period or at such a time as ajudicial declaration stated that the patent
at issue was invalid or not infringed. 50 Thus, it was in Pfizer's interest
to avoid judicial scrutiny of the patent, pending the completion of
IVAX's exclusivity period.
Apotex responded by filing an action against Pfizer, seeking a
declaration that its generic drug does not infringe the patent at is-
sue.5' The district court granted Pfizer's motion to dismiss, holding
that neither (1) Pfizer's Orange Book listing, (2) Pfizer's suit against
WAX, (3) Pfizer's history of litigation against other generic drug com-
panies (regarding other Pfizer patents and generic versions of Pfizer
products), nor (4) Pfizer's refusal to agree that Apotex does not in-
fringe created the requisite reasonable apprehension of suit.5 2 Along
the way, the district court rejected Pfizer's argument that the then-
recently enacted "Medicare Amendments" to the Food, Drug and Cos-
metic Act 53 altered or obviated the "reasonable apprehension of suit"
requirement for patent declaratory judgment actions, stating, "The
§ 355 (j) (5) (B) (iii). However, if/when the ANDA application commences marketing the
generic drug product, the patent owner is free to sue the ANDA for infringement.
47. See Apotex, Inc. v. Pfizer Inc., 385 F. Supp. 2d 187, 190 (S.D.N.Y. 2005).
48. Id.
49. See 21 U.S.C. § 355(j) (5) (B) (iv) (2000).
50. See id.
51. Apotex, 385 F. Supp. 2d at 188.
52. Id. at 194.
53. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003,
Pub. L. No. 108-173, 117 Stat. 2066, amended both the Food, Drug and Cosmetic Act and
the Patent Act to provide that if the patent owner or NDA holder does not sue the ANDA
applicant within forty-five days of receiving notice of the ANDA submission, the ANDA
applicant may seek a declaratory judgment of non-infringement or invalidity. See 21 U.S.C.
§ 355(j)(5) (C); 35 U.S.C. § 271(e)(5) (2000). The latter provides that in such circum-
stances, "the courts of the United States shall, to the extent consistent with the Constitu-
tion, have subject matter jurisdiction in any action brought by such person under section
2201 of title 28 for a declaratory judgment that such patent is invalid or not infringed." 35
U.S.C. § 271 (e) (5).
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Medicare Amendments do not disturb the Federal Circuit's consistent
holding that the constitutional limits of an Article III court's jurisdic-
tion in anticipatory patent infringement declaratory judgment actions
are defined by the two-part reasonable apprehension test."54 The Fed-
eral Circuit summarily affirmed, 55 : presumably satisfied that the Apotex
facts were indistinguishable from those in Teva Pharmaceuticals USA,
Inc. v. Pfizer Inc.,56 which it had decided (in favor of the declaratory
judgment defendant) just about a year earlier.
The Federal Circuit made it clear in MedImmune and Teva that the
"reasonable apprehension of suit" requirement is jurisdictional. 57 But
policy considerations also played a role in these cases. The Federal
Circuit held that MedImmune was controlled by Gen-Probe, where the
court cited the "undesirable results" that would result were it to per-
mit a non-breaching licensee to sue, namely:
Allowing this action to proceed would effectively defeat [the] con-
tractual covenants [of the license] and discourage patentees from
granting licenses. In other words, in this situation, the licensor
would bear all the risk, while [the] licensee would benefit from the
license's effective cap on damages or royalties in the event its chal-
lenge to the patent's scope or validity fails. 58
In his dissent from the court's denial of Teva's petition for panel re-
hearing and rehearing en banc, Judge Gajarsa noted, "The Teva court
54. Apotex, 385 F. Supp. 2d at 192-93.
55. Apotex, Inc. v. Pfizer Inc., 159 F. App'x 1013 (Fed. Cir. 2005).
56. 395 F.3d 1324, 1338 (Fed. Cir. 2005) ("[W]e agree with the district court that
Teva failed to establish that an actual controversy existed between it and Pfizer, as required
under the Declaratory Judgment Act, 28 U.S.C. § 2201(a).").
57. See MedImmune, Inc. v. Genentech, Inc., 427 F.3d 958, 964-65 (Fed. Cir. 2005)
("Thus although courts have discretion in deciding whether to accept a declaratory (judg-
ment] action when the constitutional and statutory requirements are met, there is no dis-
cretion to accept an action when there is no controversy of immediacy or reality because
there is no reasonable apprehension of suit."); Teva, 395 F.3d at 1333 ("In order for this
case to be one fit for judicial review, Teva must be able to demonstrate that it has a reason-
able apprehension of imminent suit .... This requirement of imminence reflects the Article
III mandate that the injury in fact be 'concrete,' and 'actual or imminent, not conjectural
or hypothetical.'") (emphasis in original) (quoting Maryland Cas. Co. v. Pac. Coal & Oil
Co., 312 U.S. 270, 273 (1941)); see also MedImmune, Inc. v. Centocor, Inc., 409 F.3d 1376,
1382 (Fed. Cir. 2005) ("[T]he 'Hobson's choice' [of whether to litigate or take a license]
about which MedImmune complains arises not from Gen-Probe, but from Article III's re-
quirement that, before a district court exercises jurisdiction in a declaratory judgment suit,
there must be an actual controversy between the parties.") (emphasis omitted); Gen-Probe
Inc. v. Vysis, Inc., 359 F.3d 1376, 1382 (Fed. Cir. 2004) ("Under these circumstances, there
is not a reasonable apprehension of suit. Therefore, this court holds that no actual contro-
versy supports jurisdiction under the Declaratory Judgment Act ...
58. Gen-Probe, 359 F.3d at 1382.
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ignores [relevant] precedent and reads general infringement policy
considerations into Article III, where they do not belong."59
As discussed below, Judge Gajarsa is right. The Federal Circuit's
declaratory judgment jurisprudence has been inconsistent and ambig-
uous with respect to the distinction between jurisdiction-the power of
the lower federal courts to hear declaratory judgment cases-and the
appropriate role of policy considerations-the prudence of allowing a
particular declaratory judgment action to go forward.
The Supreme Court has determined that the Federal Circuit
must revise its declaratory judgment jurisprudence, at least in some
respects. In reviewing MedImmune on certiorari, the Court recently
held that the failure of a patent licensee to cease payment of license
fees prior to bringing an action for a declaratory judgment of patent
non-infringement, invalidity, or unenforceability does not make the
declaratory judgment claim non-justiciable. 60 In so deciding, the
Court criticized the Federal Circuit's "reasonable apprehension" test,
stating that it conflicts with several Supreme Court decisions. 61 Thus,
the Federal Circuit's "reasonable apprehension" test appears to have
waning future vitality. However, an examination of how the Federal
Circuit has confused and conflated issues of judicial power under the
Act is nonetheless worthwhile because the power versus prudence dis-
tinction holds significance regardless of the standard employed by the
court.
II. Judicial Power vs. Judicial Discretion
The Federal Circuit has confused and conflated jurisdictional
and prudential facts and considerations throughout its quarter-cen-
tury-long tenure. The court's articulations of the governing standards
and its application of those standards in the appeals it hears both ex-
hibit this confusion.
59. Teva Pharm. USA, Inc. v. Pfizer Inc., 405 F.3d 990, 994 (Fed. Cir. 2005) (Gajarsa,
J., dissenting).
60. MedImmune, Inc. v. Genentech, Inc., No. 05-608, slip op. at 18 (U.S. Jan. 9,
2007), available at 2007 WL 43797.
61. Id. at 13-14 n.ll.
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A. The Justiciability Standard: Constitutional Mandate or Federal
Circuit Policy?
The Federal Circuit has recognized that the Act's actual contro-
versy requirement is constitutionally mandated 6 2 and that the Act
neither confers jurisdiction on the federal courts6 3 nor imposes juris-
dictional requirements above and beyond those compelled by the
Constitution. 64 Further, in the cases discussed herein and in many
others, 65 the court has used its reasonable apprehension test to deter-
62. See, e.g., Medlmmune, 409 F.3d at 1382 ("[T]he 'Hobson's choice' [of whether to
litigate or take a license] about which MedImmune complains arises... from Article III's
requirement that, before a district court exercises jurisdiction in a declaratory judgment
suit, there must be an actual controversy between the parties."); Fina Oil & Chem. Co. v.
Ewen, 123 F.3d 1466, 1470 (Fed. Cir. 1997) ("A declaratory judgment action permits a
threatened party to resolve its potential liability, but only when the situation has progressed
to an actual controversy, as required by Article III of the Constitution.") (citation omitted);
Arrowhead Indus. Water, Inc. v. Ecolochem, Inc., 846 F.2d 731, 735 (Fed. Cir. 1988) ("The
competing considerations are of constitutional dimension: (1) there must be an actual
controversy over which a federal court may exercise jurisdiction ... ; (2) to proceed in the
absence of a case or controversy would involve the court in rendering a forbidden advisory
opinion.") (citing Aetna Life Ins. Co. v. Haworth, 300 U.S. 227, 239-41 (1937) ("The De-
claratory Judgment Act... is operative only in respect to controversies which are such in
the constitutional sense.")); Goodyear Tire & Rubber Co. v. Releasomers, Inc., 824 F.2d
953, 955 (Fed. Cir. 1987) ("It goes without saying that federal courts do not sit to render
advisory opinions. Thus, the Declaratory Judgment Act requires the existence of an actual
case or controversy between the parties before a federal court can constitutionally assume
jurisdiction.") (citation omitted).
63. See, e.g., Foster v. Hallco Mfg. Co., Inc., 947 F.2d 469, 479 (Fed. Cir. 1991) ("With-
out that controversy, no suit under the Declaratory Judgment Act could be maintained
because, as the Supreme Court has said, the Declaratory Judgment Act gives no indepen-
dent basis for subject matter jurisdiction in district court." (citing Skelly Oil Co. v. Phillips
Petroleum Co., 339 U.S. 667, 671-72 (1950))).
64. Jervis B. Webb Co. v. Southern Sys., Inc., 742 F.2d 1388, 1398 (Fed. Cir. 1984)
("[Tihe case or controversy requirement for declaratory judgment jurisdiction has been
defined to be the same as the case or controversy requirement in the constitutional
sense.").
65. See, e.g., Capo, Inc. v. Dioptics Med. Prod., Inc., 387 F.3d 1352, 1355 (Fed. Cir.
2004) ("Declaratory justiciability of patent disputes requires both (1) a threat or other
action by the patentee whereby the declaratory plaintiff has a reasonable apprehension
that he will be sued for infringement, and (2) activity by the declaratory plaintiff that con-
stitutes the alleged infringement or active preparation to conduct such activity.") (citation
omitted); Hunter Douglas, Inc. v. Harmonic Design, Inc., 153 F.3d 1318, 1326 (Fed. Cir.
1998) ("When a declaratory judgment plaintiff alleges that the claims of a patent are not
infringed, invalid, or unenforceable, we apply a two-step test to determine whether there is
an actual controversy."), overruled on other grounds by Midwest Indus., Inc. v. Karavan Trail-
ers, Inc., 175 F.3d 1356 (Fed. Cir. 1999); Cordis Corp. v. Medtronic, Inc., 835 F.2d 859, 862
(Fed. Cir. 1987) ("In declaratory judgment patent suits, there are two prerequisites for
establishing the existence of a case or actual controversy between the parties: first, the
defendant must have engaged in conduct giving rise to a reasonable apprehension on
plaintiff's part that it will face an infringement suit or the threat of one if it commences or
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mine whether an actual controversy exists, thus effectively equating its
test with the constitutional minimum requirements.
Recently, however, several of the court's members explicitly dis-
claimed the jurisdictional essence of the reasonable apprehension
test. For example, in his opinion dissenting from the court's denial of
the petition for panel rehearing and rehearing en banc in Teva, Judge
Gajarsa (joined by Judge Dyk) wrote: "Article III does not compel [the
reasonable apprehension test], and the Supreme Court has rejected
the doctrinal rigidity [the panel opinion in Teva] introduces."66 Judge
Dyk (joined by Judge Gajarsa) went even further in his dissent, observ-
ing that the few existing Supreme Court precedents regarding Article
III and declaratory judgments "provide no support for a reasonable
apprehension of imminent suit requirement." 67 Moreover, he noted
the Ninth Circuit's use of the "reasonable apprehension [of] liability"
standard and pointed out that the First Circuit has held the "reasona-
ble apprehension" (of suit or of liability) construct "irrelevant" under
particular circumstances. 68
To be sure, the Federal Circuit has said that the reasonable ap-
prehension test is not the only vehicle that can be used to evaluate
whether an actual controversy exists.69 And on several occasions, it has
justified the test's application with reference to its asserted practical
utility. 70 But the fact is that the reasonable apprehension test has ac-
continues the activity in question; second, the plaintiff must have actually produced the
accused device or have actually prepared to produce it.") (citations omitted).
66. Teva Pharm. USA, Inc. v. Pfizer Inc., 405 F.3d 990, 991 (Fed. Cir. 2005) (Gajarsa,
J., dissenting).
67. Id. at 996-97 (Dyk, J., dissenting).
68. Id. at 997 (citing Societe de Conditionnement en Aluminium v. Hunter Eng'g
Co., 655 F.2d 938, 944 (9th Cir. 1981) (emphasis in original); Sallen v. Corinthians
Licenciamentos LTDA, 273 F.3d 14 (1st Cir. 2001)). The declaratory judgment plaintiff in
Sallen had lost his domain name in an arbitration proceeding and sued for a declaration
that he was entitled to it under United States law. Sallen 273 F.3d at 21-22. The First
Circuit held there existed a "certain controversy" sufficient for jurisdiction. Id. at 26.
69. See Fina Oil & Chem. Co. v. Ewen, 123 F.3d 1466, 1470 (Fed. Cir. 1997) ("Satisfac-
tion of th[e] traditional two-part test is not ... a prerequisite to jurisdiction in every possi-
ble patent declaratory judgment action. Indeed, the two elements merely assure that the
declaratory plaintiff has enough interest in the subject matter of the suit and that the
disagreement between the parties is real and immediate enough to fulfill the 'actual con-
troversy' requirement.").
70. See, e.g., Gen-Probe Inc. v. Vysis, Inc., 359 F.3d 1376, 1380 (Fed. Cir. 2004)
("Through its cases, this court has developed a pragmatic inquiry that focuses on not only
the conduct of the patentee but also the conduct of the putative infringer: 'There must be
both (1) an explicit threat or other action by the patentee, which creates a reasonable
apprehension on the part of the declaratory judgment plaintiff that it will face an infringe-
ment suit, and (2) present activity which could constitute infringement or concrete steps
taken with the intent to conduct such activity.'" (quoting BP Chem. Ltd. v. Union Carbide
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ted as the pivot on which the inquiry regarding jurisdiction has turned
in most cases. Therefore, regardless of the court's characterizations of
the test as "pragmatic" and "useful," 71 the reality-especially for the
declaratory judgment plaintiffs the court has turned away for lack of a
"reasonable apprehension of suit"-is that the court has effectively el-
evated the reasonable apprehension standard to constitutional status.
If that is not true, either the court has erroneously interpreted the Act
as including jurisdictional requirements above and beyond what the
Constitution requires, 72 or it has imposed its own heightened pruden-
tial standard in the power inquiry. The former notion-that the statute
itself imposes jurisdictional conditions-cannot be squared with the
Supreme Court's interpretation of the Act, an interpretation the Fed-
eral Circuit has acknowledged. 73 The latter notion disregards congres-
sional intent, as reflected in the plain language of the statute.74
There is ample evidence that the court's "reasonable apprehen-
sion" standard has been motivated by policy concerns. For example,
the court has said that it "maintain [s] this requirement, for it 'protects
quiescent patent owners against unwarranted litigation' . . ..-75 Ac-
Corp., 4 F.3d 975, 978 (Fed. Cir. 1993); Arrowhead Indus. Water, Inc. v. Ecolochem, Inc.,
846 F.2d 731, 736 (Fed. Cir. 1988) (prefacing its application of the two-step test by describ-
ing it as a "[a] test often useful in evaluating complaints for declaratory judgments in
patent cases"))).
71. See Arrowhead, 846 F.2d at 736; Gen-Probe, 359 F.3d at 1380.
72. In the words of the Court:
The Declaratory Judgment Act of 1934, in its limitation to "cases of actual contro-
versy," manifestly has regard to the constitutional provision and is operative only
in respect to controversies which are such in the constitutional sense. The word
"actual" is one of emphasis rather than of definition. Thus the operation of the
Declaratory Judgment Act is procedural only. In providing remedies and defining
procedure in relation to cases and controversies in the constitutional sense the
Congress is acting within its delegated power over the jurisdiction of the federal
courts which the Congress is authorized to establish.
Aetna Life Ins. Co. v. Haworth, 300 U.S. 227, 239-40 (1937) (citations omitted). The Court
later elaborated:
Congress enlarged the range of remedies available in the federal courts but did
not extend their jurisdiction. When concerned as we are with the power of the
inferior federal courts to entertain litigation within the restricted area to which
the Constitution and Acts of Congress confine them, "jurisdiction" means the
kinds of issues which give right of entrance to federal courts. Jurisdiction in this
sense was not altered by the Declaratory Judgment Act.
Skelly Oil Co. v. Phillips Petroleum Co., 339 U.S. 667, 671-72 (1950).
73. See, e.g., Glaxo, Inc. v. Novapharm, Ltd., 110 F.3d 1562, 1570 (Fed. Cir. 1997)
(citing Skelly Oil, 339 U.S. at 671-21; Aetna, 300 U.S. at 240).
74. See infra notes 87-91 and accompanying text.
75. Hunter Douglas, Inc. v. Harmonic Design, Inc., 153 F.3d 1318, 1326 (Fed. Cir.
1998) (quoting Arrowhead Indus. Water, Inc. v. Ecolochem, Inc., 846 F.2d 731, 736 (Fed.
Cir. 1988)).
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cording to Judge Gajarsa, "[the Federal Circuit's] cases recognize rea-
sonable apprehension, in the typical patent infringement case, as but
a pragmatic attempt to give operational guidance against which paten-
tees can structure their conduct, and control their litigation costs, in a
fact-specific area of law. "76 And, in the licensee-in-good-standing-as-
plaintiff situation, the court explained:
[P]ermitting [the licensee] to pursue a lawsuit without materially
breaching its license agreement yields undesirable results. [The
patentee] voluntarily relinquished its statutory right to exclude by
granting [the licensee] a nonexclusive license. In so doing, [the
patentee] chose to avoid litigation as an avenue of enforcing its
rights.7
7
As the above examples show, on some occasions, the court has
substantiated its reasonable apprehension test with policy justifica-
tions. On others, however, the court has unequivocally linked its test
to both the language of the Act and to the applicable constitutional
constraints, as these excerpts illustrate:
From Sierra Applied Sciences, Inc. v. Advanced Energy Industries,
Inc. :78
Here, AEI's conduct created the requisite reasonable apprehen-
sion of suit as to Sierra's past sales of the 2 kW power supply, and
such sales in fact took place within the relevant time period, estab-
lishing the district court's Article III jurisdiction to adjudicate
whether the past sales of the 2 kW power supply constituted in-
fringement of the '813 patent, and to adjudicate whether the '813
patent is invalid. 79
From Medlmmune, Inc. v. Genentech, Inc.:80
Thus although courts have discretion in deciding whether to ac-
cept a declaratory action when the constitutional and statutory re-
quirements are met, there is no discretion to accept an action
when there is no controversy of immediacy or reality because there
is not reasonable apprehension of suit. 8 1
And from Teva Pharmaceuticals USA, Inc. v. Pfizer Inc. :82
In order for this case to be one fit for judicial review, Teva must be
able to demonstrate that it has a reasonable apprehension of immi-
nent suit. Whether there is an "actual controversy" between parties
having adverse legal interests depends upon whether the facts al-
76. Teva Pharm. USA, Inc. v. Pfizer Inc., 405 F.3d 990, 991 (Fed. Cir. 2005) (Gajarsa,
J., dissenting) (joined by Dyk, J.).
77. Gen-Probe Inc. v. Vysis, Inc., 359 F.3d 1376, 1382 (Fed. Cir. 2004).
78. 363 F.3d 1361 (Fed. Cir. 2004).
79. Id. at 1377.
80. 427 F.3d 958 (Fed. Cir. 2005).
81. Id. at 964-65.
82. 395 F.3d 1324 (Fed. Cir. 2005).
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leged show that there is a substantial controversy between the par-
ties "of sufficient immediacy and reality to warrant the issuance of a
declaratory judgment." This requirement of imminence reflects
the Article III mandate that the injury in fact be "concrete," and
"actual or imminent, not conjectural or hypothetical."83
We do not think that the cases cited by Teva support the proposition
that the reasonable apprehension of suit prong of our traditional two-part
test is not a constitutional requirement.84
We conclude that the plain language of the statute, as well as the
legislative history, support the conclusion that Congress did not in-
tend for the Medicare Amendments to cause courts to alter the
requirement of the two-part test that a declaratory judgment plain-
tiff must demonstrate a "reasonable apprehension" of suit to estab-
lish Article III jurisdiction.8 5
As the decision in Teva illustrates, the Federal Circuit has specifically
rejected a litigant's argument that the two-step test "represents a pru-
dential rule rather than a constitutional requirement."8 6 Yet, as a mat-
ter of jurisprudential integrity, the court cannot have it both ways.
Without a doubt, the Declaratory Judgment Act accommodates
the exercise of judicial discretion. The Act says "[i]n a case of actual
controversy within its jurisdiction . . . any court of the United
States... may declare the rights and other legal relations of any inter-
ested party ... ."87 And the Supreme Court has flatly confirmed,
"[T] his is an enabling Act, which confers a discretion on the courts
rather than an absolute right upon the litigant."8 8 But the Act distin-
guishes between jurisdiction and discretion, conferring upon a court
the discretion to exercise-or not-the authority it possesses to decide
"a case of actual controversy within its jurisdiction." It thus obliges its
own two-step analysis. First, the court should determine whether the
case presents an Article III controversy. Then, if (and only if) the
court concludes that it has jurisdiction to decide the dispute, should it
evaluate the relevant prudential considerations and decide whether
the exercise of jurisdiction is appropriate.
The Federal Circuit has, in fact, recognized the appropriate ana-
lytical framework. It has said, "[t] here is no absolute right to a declara-
83. Id. at 1333 (citations omitted).
84. Id. at 1335 (emphasis added).
85. Id. at 1337.
86. Id. at 1335.
87. 28 U.S.C. § 2201 (2000) (emphasis added).
88. Pub. Serv. Comm'n v. Wycoff Co., 344 U.S. 237, 241 (1952).
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tory judgment. The Act says a court 'may' grant one. Hence, when
there is a clear controversy and thus jurisdiction, a district court's de-
cision on whether to exercise that jurisdiction is discretionary. '"' 9 The
court has also shown it understands that jurisdiction is the prerequi-
site to the exercise of discretion9" and that a two-step inquiry is appro-
priately applied.91 Thus, the problem is not that the Federal Circuit
has taken policy into account in evaluating declaratory judgment jus-
ticiability. The problem is the extent to which it has permitted policy
to influence the first step-the constitutional or jurisdictional analy-
sis-as evidenced by its justifications for,92 and application of, its two-
step reasonable apprehension/infringer activity test.93
B. The Standard in Action: Which Facts Are Which?
Despite its policy justifications for the actual controversy test, the
Federal Circuit has explicitly noted that the test is jurisdictional.94
Thus, the court has recognized that the declaratory judgment plain-
tiffs ability to satisfy the reasonable apprehension prong (along with
the infringer activity prong) is a separate inquiry from whether the
court should exercise its discretion to hear or to decline to hear a
given declaratory claim under the Act.95 In determining subject mat-
89. Arrowhead Indus. Water, Inc. v. Ecolochem, Inc., 846 F.2d 731, 735 n.6 (Fed. Cir.
1988).
90. See, e.g., Spectronics Corp. v. H.B. Fuller Co., 940 F.2d 631, 634 (Fed. Cir. 1991)
("When there is no actual controversy, the court has no discretion to decide the case.
When there is an actual controversy and thus jurisdiction, the exercise of that jurisdiction
is discretionary."), quoted in Teva, 395 F.3d at 1332, Fina Oil & Chem. Co. v. Ewen, 123 F.3d
1466, 1471 n.4 (Fed. Cir. 1997), and EMC Corp. v. Norand Corp., 89 F.3d 807, 810 (Fed.
Cir. 1996).
91. See, e.g., Capo, Inc. v. Dioptics Med. Prod., Inc., 387 F.3d 1352, 1356 (Fed. Cir.
2004) (agreeing with the district court that the facts presented an actual controversy, but
vacating the court's decision on the given facts to decline to exercise jurisdiction as an
abuse of discretion); EMC Corp., 89 F.3d at 815 (holding that although EMC had estab-
lished the existence of an actual controversy, the district court did not abuse its discretion
in declining to exercise jurisdiction).
92. See supra notes 75-77 and accompanying text.
93. See infra notes 99-122 and accompanying text.
94. See supra notes 78-86 and accompanying text.
95. See EMC Corp., 89 F.3d at 815 (holding that the patentee's conduct was sufficient
to create an actual controversy conferring jurisdiction on the district court, and upholding
the district court's discretionary refusal to exercise that jurisdiction); Spectronics Corp. v.
H.B. Fuller, 940 F.2d 631, 634 (Fed. Cir. 1991) (distinguishing dismissals based on the lack
of an actual controversy, "and thus jurisdiction," and those based on discretionary author-
ity). The court in Spectronics explained the relationship between the "absolute predicate" of
an actual controversy and the discretionary authority to exercise the jurisdiction that con-
troversy confers. Id. (citing Public Serv. Comm'n v. Wycoff Co., 344 U.S. 237, 241 (1952);
Arrowhead Indus. Water, Inc. v. Ecolochem, Inc., 846 F.2d 731, 735 n.6 (Fed. Cir. 1988)).
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ter jurisdiction for declaratory judgment claims, the Federal Circuit
and the district courts sometimes have given separate attention to the
discretionary aspects of the Act as an independent inquiry to
whether 96 or not9 7 the jurisdictional prerequisite is met.98 However, as
discussed below, the courts frequendy have based actual controversy
96. See generally EMC Corp., 89 F.3d at 813-15 (evaluating the propriety of the district
court's decision not to exercise discretion over alleged infringer's declaratory judgment
claim against the patentee, even though the "actual controversy" requirement was met);
Bristol-Myers Squibb Co. v. Rh6ne-Poulenc Rorer, Inc., No. 95 Civ. 8833, 1996 WL 71492,
at *7 (S.D.N.Y. Feb. 20, 1996) (denying patentee's request that the court exercise discre-
tion and refuse to hear alleged infringer's declaratory judgment action, where an actual
controversy existed at the time the alleged infringer filed its complaint and no grounds for
an exception to the first-filed rule were shown); KPR, Inc. v. C & F Packing Co., No. 4:93-
CV-243-Y, 1993 WL 726236, at *5 (N.D. Tex. Nov. 24, 1993) (dismissing alleged infringer's
declaratory judgment claims in favor of patentee's later-filed patent infringement claims).
97. See generally Bausch & Lomb, Inc. v. Ciba Corp., 39 F. Supp. 2d 271, 274-75
(W.D.N.Y. 1999) (declining to exercise jurisdiction over contact lens manufacturer's de-
claratory judgment claim against patentee "[elven if... [manufacturer] had met the ac-
tual-controversy requirement"); Waters Corp. v. Hewlett-Packard Co., 999 F. Supp. 167, 174
(D. Mass. 1998) (basing grant of patentee's motion to dismiss on both a lack of subject
matter jurisdiction and the court's discretion to decline jurisdiction); Envtl. Dynamics, Inc.
v. Robert Tyer & Assoc., Inc., 929 F. Supp. 1212, 1249-50 (N.D. Iowa 1996) (holding that
propriety of deferring to sister court's jurisdiction over permanent injunction and right to
revisit its own judgments constitutes separate basis-apart from lack of actual contro-
versy-for dismissing declaratory judgment counterclaims).
98. In some cases, an actual controversy existing between the parties at the time suit is
filed is rendered moot by subsequent events. For example, the court may dismiss the paten-
tee's infringement claim prior to consideration of the opponent's claim for a declaration
of invalidity. See, e.g., Industrias Metalicas Marva, Inc. v. Lausell, No. 96-1697, 1997 WL
557626, at *17 (D.P.R. Aug. 28, 1997) (granting summaryjudgment to alleged infringer on
the patentee's infringement claim). Alternatively, the patentee may stipulate that the oppo-
nent's activities do not infringe the patent(s) at issue. See, e.g., Spectronics, 940 F.2d at 633
(discussing patentee's covenant not to sue, designated as a "Statement of Non Liability");
Dow Chem. Co. v. Exxon Chem. Patents, Inc., No. 94-572-SLR, 1996 WL 571541, at *3 (D.
Del. Sept. 20, 1996) (concluding that the patentee's "Statement of Nonliability is sufficient
to protect [declaratory judgment] plaintiff against any reasonable apprehension of suit for
any products it currently manufactures or has taken concrete steps to manufacture in the
future" and, consequently, dismissing claim for declaration of non-infringement and inva-
lidity). Alternatively, the patentee may promise not to sue the opponent for infringement
based on current or past activities. See, e.g., Super Sack Mfg. Corp. v. Chase Packaging
Corp., 57 F.3d 1054, 1056-57, 1059-60 (Fed. Cir. 1995) (deciding patentee's motion to
dismiss grounded on its promise, manifested in its attorney's statement in motion papers
and briefs, not to sue its opponent for infringement of the patents at issue based on the
challenger's past or current products); Newman-Green, Inc. v. AptarGroup, Inc., No. 97 C
3489, 1998 WL 178584, at *2 (N.D. Ill. Feb. 5, 1998) (granting patentee's motion to dismiss
based upon its "unconditional promise not to sue" the declaratory judgment plaintiff for
infringement in its pleading); Zip Dee, Inc. v. Dometic Corp., No. 93 C 3200, 1994 WL
8234, at *1 (N.D. Ill. Jan. 7, 1994) (evaluating the effect of the patentee's "stipula-
tion ... that it will never sue [the patent challenger] or its customers for infringement of
the patent at issue in the litigation" on its jurisdiction over the challenger's declaratory
judgment counterclaim).
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determinations in part or in whole on considerations, which should
factor, if at all, only in their discretionary ruminations. The failure to
distinguish between jurisdictional, or constitutional, considerations
on the one hand, and discretionary, or policy, considerations on the
other, has occurred with respect to both prongs of the actual contro-
versy test. Put simply, courts often have confused issues of power with
those of prudence. The potentially negative implications of the courts'
confusion justify greater attention to the distinction.
1. The "Reasonable Apprehension" Prong
In defense of its restrictive stance on the availability of declaratory
judgment relief against patentees, 99 the Federal Circuit has admon-
ished that "more is required than the existence of an adversely held
patent,"100 and "that a patent exists does not alone create a right to
challenge its validity in court."10 1 According to the court, this rule
"protects quiescent patent owners against unwarranted litigation. '" 10 2
But no credible commentator or litigant has contended that patents
are vulnerable to declaratory judgment attack merely because they ex-
ist, and such straw-men arguments have contributed little to the
analysis.
Clearly, persons with a mere academic interest in a particular pat-
ent's validity do not have standing to challenge it.13 Furthermore,
In such situations, the courts have consistently held that such subsequent events divest the
court of jurisdiction. See generally Super Sack, 57 F.3d at 1059-60 (affirming the district
court's dismissal of a declaratory judgment counterclaim and noting that the "promise not
to sue is the heart of the matter," as the resulting "estoppel ... removes.., any controversy
sufficiently actual to confer jurisdiction"); Spectronics, 940 F.2d at 638 (holding that "[t]o
proceed would 'involve the court in rendering a forbidden advisory opinion"') (quoting
Arrowhead Indus. Water, Inc. v. Ecolochem, Inc., 846 F.2d 731, 735 (Fed. Cir. 1988));
Industrias Metalicas, 1997 WL 557626, at *18 (concluding that it lacks jurisdiction over the
declaratory judgment counterclaim once the infringement claim is dismissed, in the ab-
sence of any jurisdictional grounds independent of the infringement action); Zip Dee, 1994
WL 8234, at *1 (holding that Article III and the Declaratory Judgment Act require it to
decline what amounts, under the circumstances, to a request for an advisory opinion). This
result is attributed to the constitutional and statutory requirement that the declaratory
judgment claimant demonstrate that 'jurisdiction over its declaratory judgment action ex-
isted at, and has continued since, the time the [claim] was filed." Spectronics, 940 F.2d at
635 (quoting Int'l Med. Prosthetics Research Assoc. v. Gore Enter. Holdings, Inc. 787 F.2d
572, 575 (Fed. Cir. 1986)) (emphasis omitted).
99. See supra notes 28-34 and accompanying text.
100. BP Chem. Ltd. v. Union Carbide Corp., 4 F.3d 975, 978 (Fed. Cir. 1993).
101. Int'l Med. Prosthetics Research Assoc., 787 F.2d at 576.
102. Arrowhead, 846 F.2d at 736.
103. See Precision Shooting Equip. v. Allen, 646 F.2d 313, 316 (7th Cir. 1981) (noting
that "[a] court will not render advisory opinions or expound on academic or moot ques-
tions merely to satisfy the curiosity of the parties"). Likewise, it is well established that a
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many of the cases that have presented contested issues of declaratory
judgment jurisdiction have not involved "quiescent" patentees.1 0 4
Rarely would the truly quiescent patent owner need the protection of
the actual controversy requirement of the Constitution and the Act.
Even in the absence of such a requirement, the expense and aggrava-
tion of patent litigation would deter purely academic attacks on pat-
ents. Nonetheless, courts have found jurisdiction wanting even where
patentees have engaged in substantial vexatious conduct. 10 5
More importantly, however, some courts have offered the protec-
tion of patent owners as ajustification for distinguishing between con-
stitutionally cognizable "actual controvers[ies]" and disputes of
party cannot satisfy the "infringer activity" requirement by asserting that "but for" the exis-
tence of the patent, it would engage in particular activity. Id.; see also BP Chem., 4 F.3d at
980 (rejecting as insufficient the challenger's allegations that its licensee would use a speci-
fied process in the absence of the patentee's patent). By way of comparison, the Supreme
Court has held that citizen groups who allege, by way of affidavits and testimony, that their
enjoyment of the river in question has been adversely affected by alleged violations of the
federal Clean Water Act, have standing to sue to enforce the statute. Friends of the Earth,
Inc. v. Laidlaw Envtd. Servs. (TOC), Inc., 528 U.S. 167, 183 (2000). The jurisdictional re-
quirements of the Declaratory Judgment Act were not at issue in Friends, but the Court's
holding establishes that specific "but for" averments can be sufficient to satisfy Article III
standing requirements. See id. at 183-84. Inasmuch as the standing requirements of the
Constitution and the Act are the same, see supra notes 62-64 and accompanying text, the
Supreme Court's decision in Friends undermines the notion that dismissal of a declaratory
judgment claim based on a "but for" allegation is jurisdictionally mandated. Cf BP Chem., 4
F.3d at 980 ("That a superior process is patented to another, and unavailable for use with-
out a license, does not of itself create a justiciable controversy.").
It should be noted, in this regard, that the plaintiff in BP Chemicals never alleged that a
justiciable controversy existed solely by virtue of the existence of the patent. The plaintiff
and patentee were "competitors in the business of licensing technology for the manufac-
ture of polymers of ethylene." Id. at 976. During license negotiations with existing and
potential licensees of the challenger, the patentee had made statements concerning the
strength of its patent and its intent to enforce the patent. See id. at 978-80. The challenger
alleged that the patent was invalid and/or unenforceable. Thus, the parties's controversy
extended beyond the challenger's wish that there were no such patent.
The BP Chemicals court's "superior process" comment is one example of the courts's ten-
dency to set up ajurisdictional "strawman" when discussing the justiciability of declaratory
judgment claims. See also Precision Shooting Equip., 646 F.2d at 316; Howard T. Markey (for-
merly the ChiefJudge of the Federal Circuit), On Simplifying Patent Trials, 116 F.R.D. 369,
377 n.15 (1987) (remarking, on the subject of declaratory judgmentjurisdiction in patent
cases, that "[c]ourts have no roving commission to destroy every invalid patent"). Such
hyperbole, of course, does little to advance the inquiry in particular cases.
104. See supra note 103 and accompanying text.
105. See, e.g., SRI Int'l, Inc. v. Advanced Tech. Lab., Inc., 127 F.3d 1462, 1469-70 (Fed.
Cir. 1997); Phillips Plastics Corp. v. Kato Hatsujou Kabushiki Kaisha, 57 F.3d 1051, 1052-54
(Fed. Cir. 1995).
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hypothetical or abstract character. 10 6 Yet protecting patent owners, a
concededly laudable objective, ought to be regarded as a matter of
legislative or judicial policy. It definitely is not a matter of the federal
courts' constitutional power. Put another way, the actual controversy
issue concerns the jurisdiction of the federal district courts, not patent
policy; it is not a matter of prudence.
In addition, many of the factors courts have relied on to justify
denials of jurisdiction on the basis that the reasonable apprehension
prong is not satisfied do not bear on their power to hear the declara-
tory judgment claim. For example, in the past, accused infringers who
initiated declaratory judgment actions while in license or settlement
negotiations could have expected to have the courthouse door
slammed in their faces.10 7 The courts generally have deemed the pat-
entee's willingness to engage in negotiations as negating any reasona-
ble apprehension of suit on the part of the potential infringer, even
where it has not promised to forbear initiating its own suit.1 0 8 The
courts have similarly regarded other factors as having constitutional
significance in the jurisdictional calculus, such as the fact that the pat-
entee's in-house executive (as opposed to outside counsel) sent the
patentee's "cease and desist,"109 that the potential infringer initiated
106. See, e.g., Hunter Douglas, Inc. v. Harmonic Design, Inc., 153 F.3d 1318, 1326-27
(Fed. Cir. 1998) ("We have maintained this requirement, for it 'protects quiescent patent
owners against unwarranted litigation' under Title 35. The 'reasonable apprehension'
prong of the two-part test thus contributes to policing the boundary between a constitu-
tional controversy, which is judicially cognizable under the Declaratory Judgment Act, and
'a difference or dispute of a hypothetical or abstract or character,' which is not.") (quoting
Arrowhead, 846 F.2d at 736; Aetna Life Ins. Co. v. Haworth, 300 U.S. 227, 40 (1937)) (cita-
tions omitted).
107. See, e.g., Phillips, 57 F.3d at 1053-54 (regarding the "ongoing license negotiations"
between the patentee and a potential infringer as a significant factor in negating the exis-
tence of an actual controversy); Shell Oil Co. v. Amoco Corp., 970 F.2d 885, 888 (Fed. Cir.
1992) (holding that the patentee's statement that the declaratory judgment claimant's ac-
tivities "fall within" the claims of the patent was not an express charge of infringement and
did not give rise to a reasonable apprehension of suit because it was made in the context of
license negotiations).
108. See Shell Oil, 970 F.2d at 888.
109. See, e.g., Dataline, Inc. v. MCI WorldCom Network Serv., Inc., No. 00 Civ. 1578,
2001 WL 102336, at *4 (S.D.N.Y. Feb. 6, 2001).
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the contact between the parties,1 10 or even that the patentee was not a
large business concern.' 11
In reality, however, these factors in no way negate the existence
of a real, immediate, legal controversy between the parties. As the Fed-
eral Circuit has itself acknowledged, the potential infringer's partici-
pation in license negotiations is often principally attributable to the
patentee's spoken or unspoken threat of litigation.1 12 By the same to-
ken, the potential infringer's willingness to engage in negotiations
does not necessarily mean that it lacks a valid basis for challenging the
patent. Both parties are presumably at the negotiation table, at least in
part, to try to avoid the substantial costs associated with patent litiga-
tion.11 3 And relying on the fact that the patentee communicated via its
in-house executive, that the potential infringer contacted the patentee
first, or that the patentee is "small" in order to conclude that a federal
court lacks power to adjudicate is no less absurd. When a real, con-
crete, and substantial dispute about a patent's validity, enforceability,
or infringement exists between a patentee and a putative infringer
who will otherwise suffer injury, the federal courts have the authority
to declare the rights and obligations of the parties. Factors such as
who contacted whom first or the size of the patentee may constitute
good reason for refusing to exercise, on a discretionary basis, the juris-
diction the court possesses. But these factors do not change the fact
that a true controversy exists between the parties, and they should not
110. See, e.g., CAE Screenplates, Inc. v. Beloit Corp., 957 F. Supp. 784, 790 (E.D. Va.
1997) (including among its reasons for holding that there was no reasonable apprehension
of suit, the fact that the contact between the declaratory judgment plaintiff and the paten-
tee was initiated by the plaintiff).
111. See, e.g., Ryobi Am. Corp. v. Peters, 815 F. Supp. 172, 175 (D.S.C. 1993) (noting
that the patentee is "an individual who has created a small side line business in his home
workshop").
112. EMC Corp. v. Norand Corp., 89 F.3d 807, 811 (Fed. Cir. 1996). In the words of
the court:
To be sure, any time parties are in negotiation over patent rights, the possibility
of a lawsuit looms in the background. No patent owner with any sense would
open negotiations by assuring his opposite party that he does not intend to en-
force his patent rights under any circumstances. The threat of enforcement-
either directly by the patentee or indirectly by a third party to whom the patentee
licenses or sells the patent-is the entire source of the patentee's bargaining
power .... Thus, it is unrealistic to suggest that some negotiating patentees in-
tend to enforce their patents while some do not, and that the first group is subject
to declaratory judgment jurisdiction while the second is not.
Id. (citation omitted).
113. The results of a recent survey indicate that the average cost of patent litigation
where the amount at issue is between $1 million to $25 million is well over $2 million. See
Am. INTELL. PROP. LAw ASS'N, REPORT OP THE ECONOMIC SURVEY 22-23 (2005).
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be held to negate the actual controversy required by the Act and the
Constitution. " 1 4
In many cases, allocating factors such as these, which do not ne-
gate the existence of a real, immediate controversy, to the discretion-
ary analysis will not change the outcome of the case. In such cases,
only the basis on which the court's decision to hear or dismiss the
declaratory judgment claim will change." 5 Nevertheless, it is impor-
tant, for many reasons, to distinguish between constitutional and stat-
utory bases for denying jurisdiction and those bases founded in policy
considerations. " 1
6
2. The "Infringer Activity" Prong
The courts also have confused jurisdictional and policy considera-
tions when evaluating the sufficiency of the potential infringer's activ-
ity. As noted above, the courts have professed to permit patent
challengers to proceed with declaratory judgment claims, assuming
the requisite reasonable apprehension, even if they are not presently
engaging in infringing activity. 17 "Meaningful preparation" to engage
in activity that could constitute infringement has been said to be
enough.1 18 Nevertheless, even where infringers have engaged in sig-
nificant preparatory activity, the courts have dismissed their declara-
tory judgment claims on the ground, inter alia, that the potentially
infringing products could change before the infringers finalize and
114. In one of the relatively few decisions carefully distinguishing between jurisdic-
tional (i.e., constitutional or statutory) and prudential (i.e., discretionary or policy) consid-
erations in the context of patent declaratory judgment claims, the jurisprudential
significance of license negotiations was explained as follows:
In many cases . . . , it is the threat of litigation which serves as the motivating
factor for negotiation. This being the situation, it is more analytically sound to
treat the questions of settlement and negotiation as part of the discretion issue. In
other words, an explicit threat of patent litigation gives rise to a reasonable appre-
hension of suit and simultaneously provides the initiative to enter negotiations
designed to avoid that litigation. The controversy thus becomes ripe for adjudica-
tion as soon as the initial threat of patent litigation is made; but so long as one
party reasonably relies on the forbearance of the other duing subsequent negoti-
ations, there may be equitable and public policy reasons for discretionary dismis-
sal of a declaratory action when one party unfairly takes advantage of that
forbearance to secure a more convenient forum.
Agridyne Tech., Inc. v. W.R. Grace & Co., 863 F. Supp. 1522, 1527 n.6 (D. Utah 1994).
115. See id. (noting that its proposed reshuffling of the jurisdictional analysis would not
change the outcome in that case).
116. See infra Part III.
117. See supra notes 17, 19, and accompanying text.
118. See supra note 19 for a description of the various formulations of the test for
infringer activity.
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market them. In so doing, the courts have mistaken the jurisdictional
significance of the potential for product evolution.
For example, in Intermedics, Inc. v. Ventritex Co., 19 the Federal Cir-
cuit held that no actual controversy existed to support a patentee's
request for declaratory relief when the product at issue, an implant-
able defibrillator, had not yet received FDA approval.' 20 According to
the court, two factors supported its conclusion: (1) the uncertainty
regarding when approval might be obtained; and (2) the possibility
that the FDA could require changes to the device. 121 However, even if
a court declines to exercise jurisdiction over a declaratory judgment
claim because it views the present expenditure of the court's time and
effort as unjustified in light of anticipated changes to the product,
such a decision concerns matters of prudence-not the court's power to
hear the case. 122
III. Power vs. Prudence: It Matters in Patent Cases
A. Why the Distinction Matters
The outcome of many justiciability determinations affecting de-
claratory judgment claims in patent cases will be the same regardless
of whether a court invokes constitutional or prudential rationales. 123
119. 991 F.2d 808, No. 92-1076, 1993 WL 87405, at *1 (Fed. Cir. Feb. 22, 1993) (un-
published table decision).
120. See id., at *4; see also Telectronics Pacing Systems, Inc. v. Ventritex, Inc., 982 F.2d
1520, 1527 (Fed. Cir. 1992) (affirming district court decision that it lacked jurisdiction
over a patentee's claim for a declaratory judgment of infringement in part because
"[t]here was no certainty that the device [at issue] when approved [by the Food and Drug
Administration] would be the same device that began clinical trials").
121. Intermedics, 1993 WL 87405, at *4.
122. The Federal Circuit in Intermedics raised the uncertainty regarding the timing of
FDA approval and the possibility that changes would occur to the device in the context of
its discussion of the jurisdictional requirement of an actual controversy under the Declara-
tory Judgment Act. See Intermedics, 1993 WArL 87405, at *4. And the district court had dis-
missed the patentee's declaratory judgment claim on the ground that there was no case or
controversy between the parties. See Intermedics, Inc. v. Ventritex Co., 775 F. Supp. 1269,
1289-90 (N.D. Cal. 1991). However, the court intermixed the jurisdictional and discretion-
ary aspects of the Act in upholding the district court's judgment of dismissal. Compare Tele-
tronics, 982 F.2d at 1527 (holding that patentee's declaratory judgment action against
accused infringer's pre-FDA approval-stage device could not be maintained on the grounds
that (1) the district court lacked jurisdiction to hear it and (2) dismissal in the exercise of
discretion was appropriate), with Intermedics, 1993 WAVL 87405, at *4 ("For these reasons, the
district court did not abuse its discretion in determining not to exercise its declaratory
judgment jurisdiction for failure to meet the actual controversy requirement of [the
Act].").
123. See, e.g., Agridyne Tech., Inc. v. W.R. Grace & Co., 863 F. Supp. 1522, 1527 n.6 (D.
Utah 1994) (distinguishing between constitutional and policy bases for its determination
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For example, a decision that pending license negotiations negate an
actual controversy places, to a certain extent, 24 a declaratory judg-
ment claimant in the same position as a decision that the ongoing
discussions between the parties serve as an appropriate basis for de-
clining to exercise jurisdiction-in both instances the claimant will be
out of court. Nevertheless, it is important for courts to carefully distin-
guish between the two justiciability rationales in patent cases.
For one thing, the basis for the district court's justiciability deci-
sion determines the standard of review on appeal. 25 A district court's
decision on whetherjurisdiction exists on particular facts is a question
of law, reviewable de novo. t26 In contrast, a discretionary declination
of jurisdiction is reviewed pursuant to the more deferential "abuse of
discretion" standard. 127 In either event, the court's findings with re-
spect to the underlying facts are reviewed for clear error pursuant to
Federal Rule of Civil Procedure 52(a).128 Accordingly, a decision dis-
missing a declaratory judgment claim as a matter of discretion is less
subject to reversal on appeal than one made on the same facts but
based on the grounds that one or both of the jurisdictional prongs has
not been met.
Also, the Declaratory Judgment Act on its face precludes the con-
sideration of prudential factors in the jurisdictional calculus, as the
language of Congress made distinct the Act's jurisdictional and discre-
tionary aspects. 129 Litigants are entitled to have the statute applied as
Congress intended.
Furthermore, to the extent that the courts inconsistently assign
jurisdictional instead of prudential weight to the same or similar facts
in declaratory judgment justiciability determinations, outcomes are
less predictable. As a result, some potential infringers may be more
inclined to initiate litigation rather than acquiesce to royalty de-
mands, while others, unable to justify the cost of potentially extensive
of justiciability but noting that the case's outcome would be the same under either
analysis).
124. The trial court's rationale for its justiciability determination may affect the ulti-
mate result if the aggrieved party appeals because it determines the standard of review. See
infra notes 125-28 and accompanying text.
125. See Capo, Inc. v. Dioptics Med. Prod., Inc., 387 F.3d 1352, 1354 (Fed. Cir. 2004).
126. BP Chem. Ltd. v. Union Carbide Corp., 4 F.3d 975, 978 (Fed. Cir. 1993) (citing
Shell Oil Co. v. Amoco Corp., 970 F.2d 885, 888 (Fed. Cir. 1992)).
127. See Capo, 387 F.3d at 1354 (citing Wilton v. Seven Falls Co., 515 U.S. 277, 289
(1995)).
128. FED. R. Civ. P. 52(a); BP Chem., 4 F.3d at 978 (citing Arrowhead Indus. Water, Inc.
v. Ecolochem, Inc., 846 F.2d 731, 735 (Fed. Cir. 1988)).
129. See supra notes 87-91 and accompanying text.
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motion practice on justiciability on top of the costs and risks of litigat-
ing on the merits, may forgo business opportunities.
Most importantly, from the standpoint of maintaining a strong
national patent system, the courts are more likely to carefully evaluate
the policy implications of justiciability determinations when they are
attentive to the distinction between the jurisdictional and prudential
bases for those decisions. Litigants, in turn, will be motivated to pro-
vide courts with more careful analysis. The likely results include the
development of better policy and improved judicial decision-making.
B. Some Reasons for the Current Approach
The Federal Circuit's tendency to decide declaratory judgment
justiciability issues on jurisdictional grounds-even where the facts
more appropriately implicate policy-may be attributed to any of sev-
eral motivations. First, Congress created the court to standardize and
stabilize national patent law130 and to restore confidence in the
United States patent system.131 By discouraging decisions on pruden-
tial grounds, the Federal Circuit's approach has tended to shield pat-
entees against declaratory judgment attack. Second, it has cultivated
district court decisions subject to plenary review, giving the Federal
Circuit greater jurisprudential control. Furthermore, deciding cases
on legal, as opposed to discretionary, grounds may have helped to
shield judges from criticisms of judicial activism, and, to the extent
courts have made and sustained justiciability determinations on con-
stitutional grounds, they have constrained Congress's ability to pro-
vide declaratory judgment claimants with greater access to the
courts.1
32
Restricting access to the declaratory judgment remedy in patent
cases likewise can be justified on many grounds. For example, readily
subjecting patents to declaratory judgment attack would tend to un-
dermine the respect Congress created the Federal Circuit to engen-
130. See S. REP. No. 97-275, at 4 (1981) (Conf. Rep.) ("The creation of the Court of
Appeals for the Federal Circuit provides ... a forum for appeals from throughout the
country in areas of the law where Congress determines that there is special need
for... uniformity."); see also Atari, Inc. v.JS & A Group, Inc., 747 F.2d 1422, 1437 (Fed. Cir.
1984).
131. See, e.g., Jon F. Merz & Nicholas M. Pace, Trends in Patent Litigation: The Apparent
Influence of Strengthened Patents Attributable to the Court of Appeals for the Federal Circuit, 76J.
PAT. & TRADEMARK OFF. Soc'Y 579, 579 (1994) (noting the court's progress toward meeting
the goal of promoting predictability).
132. Although Congress cannot affect constitutional jurisdictional limits, it can change
or abrogate prudential limitations. See, e.g., United Food & Commercial Workers Union
Local 751 v. Brown Group, Inc., 517 U.S. 544, 551 (1996).
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der, for litigation raises questions about, and potentially impairs, a
patent's vitality. Furthermore, a restrictive justiciability approach also
encourages competitors to allocate resources away from litigation and
toward meaningful "design-around" efforts, stimulating innovation
that benefits the public as well as the innovator.1 33 The approach also
encourages dispute resolution via negotiation by placing the litigation
alternative effectively out of reach until after negotiations have clearly
broken down, 3 4 and, to that extent, it reduces the incidence of litiga-
tion, with all the attendant benefits.
Similarly, the courts' past reluctance to entertain declaratory
judgment claims when there was a possibility that the product at issue
may change in the future has some merit. To the extent that a prod-
uct under development may undergo modifications relevant to the
question of infringement before being introduced into the market-
place, there is a risk that resources-those of the court and of the
parties-invested in determining patent coverage may be wasted. Ad-
ditionally, it may be difficult or impossible to determine whether a
declaration of infringement or noninfringement is appropriate in cir-
cumstances where the product does not yet exist. 135 Such circum-
133. As the Federal Circuit has observed, designing around patents is socially desirable
activity:
Designing around patents is.. . one of the ways in which the patent system works
to the advantage of the public in promoting progress in the useful arts, its consti-
tutional purpose. Inherent in our claim-based patent system is also the principle
that the protected invention is what the claims say it is, and thus that infringe-
ment can be avoided by avoiding the language of the claims.
Slimfold Mfg. Co. v. Kinkead Indus., Inc., 932 F.2d 1453, 1457 (Fed. Cir. 1991).
134. Compare Oct-Office Systems, Inc. v. Eastman Kodak Co., 805 F. Supp. 642, 646-47
(N.D. Ill. 1992) (denying patentee's motion to dismiss accused infringer's declaratory
claim where the parties' licensing negotiations "had failed"), with Phillips Plastics Corp. v.
Kato Hatsujou Kabushiki Kaisha, 57 F.3d 1051, 1053-54 (Fed. Cir. 1995) (holding a paten-
tee's statement that declaratory judgment plaintiff's products were "covered by" its patent
did not give rise to an actual controversy because the patentee had also offered a license
and "[w]hen there are proposed or ongoing license negotiations, a litigation controversy
normally does not arise until the negotiations have broken down"), Shell Oil Co. v. Amoco
Corp., 970 F.2d 885, 889 (Fed. Cir. 1992) (affirming dismissal of accused infringer's declar-
atory judgment action where patentee's statements that the accused infringer's activities
"'fall within,' are 'covered by,' and are 'operations under'" the patentee's patent were
made during license negotiations initiated by the accused and noting "[i]t is possible that,
even after the conversations reached an impasse, [the patentee] might never have sued"),
and Century Indus., Inc. v. Wenger Corp., 851 F. Supp. 1260, 1264-65 (S.D. Ind. 1994)
(dismissing alleged infringer's declaratory judgment claim in part because the parties were
"still engaged in discussions aimed at resolving the potential dispute as late as" a week
before suit was initiated).
135. See, e.g., Lynn C. Tyler, Injunctions Against Threatened Patent Infringement: Were Lang
Pacific Marine and Its Progeny Wrongly Decided, 4 FED. CIR. B.J. 113, 133-34 (1994) (citing
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stances likely increase the risk of erroneous infringement
determinations. 13
6
These concerns, however, do not justify refraining from issuing
declaratory judgments regarding infringement in every case. Manufac-
turers frequently modify products even after they are built, intro-
duced, and sold. If the potential for change justified declining to
decide infringement, justiciable patent cases would be rare. In addi-
tion, patent infringement determinations often must be made without
examination by the court or the jury of the actual accused device. For
example, where the size or nature of the product precludes its exami-
nation in court, surrogates such as drawings, diagrams, and computer
simulations are often employed in the product's stead. 13 7 And patent
attorneys routinely evaluate infringement and potential infringement
based solely on written and oral descriptions, diagrams, or drawings of
the product or process at issue. 13 8
Furthermore, many declaratory judgment claims seek adjudica-
tion of patent validity or enforceability. Such determinations do not
require an evaluation of any potentially infringing products.
It is true that determining what the claim language means is a
critical step in determining validity or infringement. 139 Furthermore,
courts construe patent claims the same way for both purposes, 140 and
a court's decision on claim construction will, as a legal or practical
decisions refusing to grant injunctions against threatened infringement on the ground
that the product is not yet in existence).
136. See William M. Landes & Richard A. Posner, The Economics of Anticipatory Adjudica-
tion, 23 J. LEGAL STUD. 683, 690 (1994) (factoring the risk of error attributable to the
"information deficit" that may characterize anticipatory adjudication into an economic
evaluation of the risks and benefits of, inter alia, declaratory judgment determinations).
137. See Tyler, supra note 135, at 134 (commenting on the use of manufacturing draw-
ings in infringement determination).
138. Virtually every legal or equitable issue that can arise in a patent matter turns on
the language of the patent claims at issue. As a result, attorneys, judges, and litigants are
very accustomed to making patent-related evaluations based on textual and diagrammatic
descriptions alone.
139. See, e.g., SuperGuide Corp. v. DirecTV Enter., Inc., 358 F.3d 870, 874 (Fed. Cir.
2004) ("A determination of infringement involves a two-step analysis, the first step being to
properly construe the asserted claims."); SIBIA Neurosciences, Inc. v. Cadus Pharm. Corp.,
225 F.3d 1349, 1355 (Fed. Cir. 2000) ("The first step in any invalidity analysis is claim
construction. .. ").
140. See, e.g., SmithKline Beecham Corp. v. Apotex Corp., 439 F.3d 1312, 1316 (Fed.
Cir. 2006) ("[Claims must be construed the same way for validity and for
infringement . . ").
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matter, often resolve the question of infringement.14' Without a
doubt, therefore, attorneys and litigants often prefer to develop their
positions on claim construction with the potentially infringing prod-
uct in mind. And the court's understanding of the product at issue
may, similarly and appropriately, inform claim construction determi-
nations. Nevertheless, courts can make correct validity determinations
without the potentially infringing product. And the cases demonstrate
that litigants are sometimes willing to obtain binding validity, enforce-
ability, or even infringement determinations before development or
construction of the potentially infringing product or process is com-
plete. Thus, the courts should not, as a matter of law, refuse to adjudi-
cate declaratory judgment claims in such circumstances.
C. One Example of an Appropriate Resolution
The decision on a plaintiffs motion to reconsider the court's re-
fusal to dismiss a defendant's declaratory judgment counterclaim in
Farmaceutisk Laboratorium Ferring A/S v. Solvay Pharmaceuticals, Inc.,142
illustrates an appropriate resolution where patent validity is chal-
lenged in the pre-infringement stage. The plaintiff-patentee ("FLF")
sued the defendant ("Solvay"), asserting that Solvay's manufacture
and distribution of a pharmaceutical product to physicians infringed
FLF's patent.1 43 Solvay responded with a declaratory judgment coun-
terclaim, requesting that the court declare FLF's patent invalid and
not infringed.144 Solvay moved for summary judgment on FLF's in-
fringement claims, relying on the experimental use "safe harbor" de-
fense to infringement found in United States Code section
271 (e) (1).145 FLF then moved to dismiss its infringement claims after
learning through discovery that Solvay's activities were not actiona-
ble 146 and, further, to dismiss Solvay's counterclaim on the ground
that dismissal of the infringement claims dissolved the actual contro-
versy between the parties. 147
The court found that Solvay continued to possess a reasonable
apprehension of suit because its existing immunity stemmed only
141. See, e.g., Netword, LLC v. Centraal Corp., 242 F.3d 1347, 1350-51 (Fed. Cir. 2001)
("The court's construction of the claims often decides the question of infringement,
whether literal infringement or under the doctrine of equivalents.").
142. 25 U.S.P.Q. 2d 1344 (N.D. Ga. 1992).
143. See id. at 1346.
144. See id.
145. 35 U.S.C. § 271(e)(1) (2000).
146. Farmaceutisk Laboratorium, 25 U.S.P.Q. 2d at 1347.
147. Id.
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from the fact that its product was still undergoing testing as required
for Federal FDA approval 148 and because FLF had demonstrated its
intent to enforce its patent.14 9 The court further found that Solvay
had satisfied the "infringer activity" prong of the jurisdiction test by
showing "meaningful preparation" for potentially infringing
activity. 150
Although determining that an actual controversy existed between
the parties, the Farmaceutisk Laboratorium court declined to adjudicate
Solvay's non-infringement declaratory judgment claim, citing the pos-
sibility that the product could change. 151 However, the court severed
the non-infringement issue and permitted Solvay's invalidity claim to
proceed.152
The court based its decision to sever on several factors. It noted
that "[u]nlike the . . .product, the patent is a fixed target" and that
"[a] finding of invalidity would settle the issue now, without requiring
the wasting of additional resources."'153 Apparently anticipating or re-
sponding to concerns that the parties might attempt to take inconsis-
tent positions in separate validity and infringement trials, the court
observed that "any ruling concerning the patent claims will be binding
on the parties in the future[, which] . .. in turn will prevent FLF from
winning both issues by arguing contrary interpretations in severed ju-
dicial proceedings." 154
The court also discussed the policy considerations underlying its
decision:
The practical effect of this ruling is to permit those who seriously
wish to practice an art facially preempted by a patent to test the
patent's validity before completing the arduous task of obtaining
administrative approval without requiring the court to participate
in speculation as to the potential infringement of a product whose
148. Id. at 1349. Although FLF had signed a "statement of non-liability as to [Solvay's]
past and current activities" and was willing to "stipulate non-liability as to future similar
activities," the court held that Solvay's reasonable apprehension persisted because the "fu-
ture similar activities" covered only future testing activities, which were, in any event, insu-
lated by the section 271(e)(1) safe harbor. Id. Solvay's clear intent was to market the
product commercially upon FDA approval. See id.
149. Id.
150. Id. at 1351.
151. Id. at 1351-52.
152. Id. at 1351.
153. Id.
154. Id.
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final formulation has not yet been settled. This position is sup-
ported by the purpose and objectives of patent law in general.1 5
Moreover, the court recognized the effect a determination of non-
justiciability would have on Solvay:
In order to complete the project to the point of being able to mass
produce and market its product, Solvay will have committed sub-
stantial resources in both time and money .... Solvay ... simply
does not want to assume the financial risk of pending litigation
years down the road after having expended significant additional
resources on the project. 156
As noted above, the Farmaceutisk Laboratorium court relied on its
discretionary authority under the Declaratory Judgment Act in sever-
ing the issues of infringement and validity.1 57 In explaining its deci-
sion, the court expressly noted the role judicial discretion should play
in determining which circumstances justify the adjudication of a de-
claratory judgment claim.' 58 The court's attentiveness to the distinc-
tion between jurisdictional and discretionary considerations and its
recognition of the role discretion should play in distinguishing be-
tween what is justiciable and what is non-justiciable is commendable.
Farmaceutisk Laboratorium originated as a patentee's infringement
action, 15 9 and the court spoke specifically of the plight of the drug
manufacturer as being subject to the uncertainty associated with the
FDA approval process. 1 60 Different circumstances may well justify a
different outcome. Yet the court's approach to evaluating justiciability
in patent cases can advantageously be applied in other circum-
stances. 16 1 When, for example, the action is initiated by the potential
infringer, the court may determine that it has jurisdictional authority
to hear the plaintiff's claim(s) before it evaluates whether that juris-
155. Id. at 1352. Specifically, the court cited Congress's intent to "protect patent hold-
ers' rights, while encouraging improved products to enter the market and while fostering
competition to the maximum extent possible." Id.
156. Id. at 1350.
157. See supra note 151 and accompanying text.
158. Farmaceutisk Laboratorium, 25 U.S.P.Q. 2d at 1353.
159. See supra note 143 and accompanying text. As the court noted, the patentee's as-
sertion of infringement claims unambiguously signaled its willingness to enforce its patent
against the defendant. See Farmaceutisk Laboratorium, 25 U.S.P.Q. 2d at 1349. In so doing,
the patentee provided the requisite "reasonable apprehension," satisfying, in the first in-
stance, the requirement for an actual controversy. See id.
160. See supra note 155 and accompanying text.
161. The decision in Farmaceutisk Laboratorium has received little attention in the courts
and commentary. One court has declined to apply the case, stating only that "the Supreme
Court and Federal Circuit cases provide sufficient guidance to decide the issues" raised by
the parties before it. Infinitech, Inc. v. Vitrophage, Inc., 842 F. Supp. 332, 337 n.3 (N.D. Ill.
1994).
Winter 2007] POWER OR PRUDENCE
UNIVERSITY OF SAN FRANCISCO LAW REVIEW
diction ought to be exercised under the particular circumstances of
the case. Assuming that the potential infringer has demonstrated its
intent to engage in potentially infringing activity by making "meaning-
ful preparations" 162 and has (and has pleaded) a good-faith basis for
challenging the validity and/or enforceability of the patent, the court
should not regard the fact that the product or process in question is
not complete and on the market as depriving it ofjurisdiction to adju-
dicate validity and enforceability, 163 if not infringement as well. The
court should, of course, evaluate whether an exercise of its jurisdic-
tion is appropriate on the circumstances of a particular case.
For example, the fact that the product in question in Farmaceutisk
Laboratorium was a pharmaceutical product subject to FDA approval
appropriately informed the court's decision to exercise its jurisdiction
only to the point of adjudicating validity.164 The potential infringer
had a good-faith basis for challenging the patent's validity. 165 How-
ever, at a time when the Federal Circuit overturns nearly forty percent
of district court patent claim construction decisions, 166 it is clear that
even the most reasonable, well-founded basis for a party's position on
validity is no guarantee of success in litigation. 167 Under such circum-
stances, the court in Farmaceutisk Laboratorium was appropriately con-
cerned that the potential infringer would invest significant effort and
expense, above and beyond that which it had already invested, com-
pleting FDA-required clinical trials-all the while laboring under the
uncertainty that it might be enjoined when it completed the develop-
ment and approval process. 168 The court's rationale in this regard ap-
plies with equal force to other development ventures requiring
significant resources.
162. See supra note 19 and accompanying text.
163. As previously noted, supra notes 137-54 and accompanying text, in many cases it is
possible to correctly determine validity and enforceability and thus to declare the rights
and obligations of the parties as to that issue, even when the product is not complete.
164. See supra note 153-56 and accompanying text.
165. Farmaceutisk Laboratorium Ferring A/S v. Solvay Pharmaceuticals, Inc., 25 U.S.P.Q. 2d
1344, 1353 (N.D. Ga. 1992).
166. See Christian Chu, Empirical Analysis of the Federal Circuit's Claim Construction Trends,
16 BERKELEY TECH. L.J. 1075, 1090 (2001) (concluding that nearly 40% of district court
claim construction determinations are overturned by the Federal Circuit); see also Kimberly
A. Moore, Are District Court Judges Equipped to Resolve Patent Cases ? 15 HARv. J.L. & TECH. 1, 2
(2001) (citing a 33% overturn rate).
167. Whatever the reversal rate or reasons for it, it is clear that a potential infringer
who proceeds with development in the face of a presumptively valid patent assumes signifi-
cant risk, no matter how sound its invalidity or unenforceability position.
168. See supra notes 155-56 and accompanying text.
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New product development always entails investment and risk. But
the risk a party assumes in proceeding with product development
while aware of a potentially applicable patent is considerable. United
States patents are presumptively valid,' 69 and a challenger must
demonstrate invalidity or unenforceability with clear and convincing
evidence to overcome that presumption. 70 Regardless of the reasona-
bleness of its defenses, a challenger is subject to damages 71 and in-
junctive relief upon a finding of infringement. 172 If a court
determines that the allegedly infringing defendant did not exercise
due care to avoid infringement, the court may award enhanced dam-
ages of up to three times the actual damages.' 73 Furthermore, the
same determination can lead the court to declare the case "excep-
tional" and, thus, to award the patentee its reasonable attorney fees.174
These realities should always factor into a court's decision to exercise
or decline to exercise declaratory judgment jurisdiction.
Furthermore, the courts have often proclaimed the public policy
of preventing owners of invalid patents from exercising monopoly
power.' 75 In evaluating the justiciability of declaratory judgment
claims in patent cases, the courts should keep in mind that an invalid
patent ought to have absolutely no effect on the market. To the extent
a holder of an invalid patent can discourage investment or extract
what amounts to ransom in the form of unfounded settlements, such
patents are, in fact, given effect. Correctly applying the Declaratory
Judgment Act to patent disputes could limit the market effect of inva-
lid patents and thereby foster greater respect for the patent system.
169. 35 U.S.C. § 282 (2000).
170. See, e.g., Kao Corp. v. Unilever U.S., Inc., 441 F.3d 963, 968 (Fed. Cir. 2006) ("Be-
cause patents are presumed to be valid, see 35 U.S.C. § 282, an alleged infringer seeking to
invalidate a patent on obviousness grounds must establish its obviousness by facts sup-
ported by clear and convincing evidence."); Agfa Corp. v. Creo Prod. Inc., 451 F.3d 1366,
1377 (Fed. Cir. 2006) ("Unenforceability due to inequitable conduct requires proof of
materiality and intent by clear and convincing evidence.").
171. See 35 U.S.C. § 284 (2000) ("Upon finding for the claimant the court shall award
the claimant damages adequate to compensate for the infringement, but in no event less
than a reasonable royalty for the use made of the invention by the infringer, together with
interest and costs as fixed by the court.").
172. See 35 U.S.C. § 283 (2000).
173. See 35 U.S.C. § 284 (2000).
174. See 35 U.S.C. § 285 (2000).
175. See, e.g., SmithKline Beecham Corp. v. Apotex Corp., 403 F.3d 1331, 1354 (Fed.
Cir. 2005) ("Both this court and the Supreme Court have recognized that there is a signifi-
cant public policy interest in removing invalid patents from the public arena.") (citing
Cardinal Chem. Co. v. Morton Int'l, Inc., 508 U.S. 83, 100 (1993)).
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IV. Conclusion
The extra-judicial resolution of business disputes doubtlessly
ought to be encouraged, and such resolutions must remain available
for those who desire them or are obligated to pursue them by fiduci-
ary duties owed, for example, to corporate shareholders. However,
Congress enacted the Declaratory Judgment Act to provide parties
with an alternative vehicle for resolving disputes. While courts may
appropriately employ the discretion afforded by the Act to encourage
business resolutions, patent owners should not be able to force such
resolutions on parties for whose benefit the legislation was enacted.
Furthermore, parties engaged in product development are not
the only ones who bear the costs even a putatively invalid patent im-
poses. To the extent the developer passes on its CoSts, 1 7 6 its customers,
shareholders, and business partners pay as well. And to the extent the
developer elects to acquiesce to royalty demands, or is effectively
forced to accept them, the public at large pays in the form of poten-
tially higher costs to use patented technology and lack of access to any
improved or alternative technologies the developer would have pro-
duced had it not elected to forgo its opportunities.
Some of these concerns may be alleviated as a consequence of the
Supreme Court's decision in MedImmune. But that decision left several
key questions unanswered. Should a district court decline to exercise
its jurisdiction to resolve a non-breaching licensee's validity challenge?
Can a licensor immunize itself from a validity challenge or, at least,
protect itself by providing for termination upon a challenge and re-
covery of attorney's fees in the event of an unsuccessful challenge?
Which circumstances trigger jurisdiction to hear patent declaratory
judgment claims-and which fall short-now that the Supreme Court
disfavors the Federal Circuit's reasonable apprehension test?
What seems apparent is that the number of patent declaratory
judgment challenges will increase in the wake of the MedImmune deci-
sion. First, some licensees will likely seek to undo, or at least renegoti-
ate, existing licenses which lack provisions that proscribe or
discourage validity challenges. Second, putative infringers will likely
ask the courts to redefine the boundary between justiciable and non-
176. Such costs may include, for example, those associated with negotiating and paying
unwarranted royalties, investing in unnecessary efforts to design around the patent,
purchasing insurance to cover infringement risks, and obtaining legal opinions to guard
against a finding of willful infringement.
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justiciable cases, since it appears that the Federal Circuit will need to
re-evaluate its "reasonable apprehension" test.
Whether applying a more analytically sound approach to jus-
ticiability determinations would result in greater access to the declara-
tory judgment remedy for putative patent infringers is unknown. As
MedImmune reminds us, a determination that jurisdiction lies does not
mean that a court will reach the merits of a patent challenge.1 77 How-
ever, by carefully distinguishing between power and prudence, the courts
can more faithfully serve the intent of Congress and respect their con-
stitutional authority, engendering more careful analysis in the briefs
of litigants and in their own opinions, as well as greater outcome
predictability.
177. See MedImmune, Inc. v. Genentech, Inc., No. 05-608, 2007 WL 43797, at *1 (U.S.
Jan. 9, 2007) (reversing on the issue ofjurisdiction but remanding for further determina-
tions on the merits at the trial court below).
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